Systems, devices, and methods for treating vascular occlusions

Information

  • Patent Grant
  • 11937834
  • Patent Number
    11,937,834
  • Date Filed
    Wednesday, July 12, 2023
    9 months ago
  • Date Issued
    Tuesday, March 26, 2024
    a month ago
Abstract
Systems and methods for the intravascular treatment of clot material within a blood vessel of a human patient. A device in accordance with embodiments of the present technology can include, for example, a plurality of interconnected struts forming a unitary structure having a proximal portion and a distal portion. The struts can form a plurality of first cells in the proximal portion and a plurality of second cells, smaller than the first cells, in the distal portion. The device can be pulled against clot material within a blood vessel to engage, disrupt, and/or capture the clot material.
Description
TECHNICAL FIELD

The present technology relates generally to systems, devices, and methods for the intravascular treatment of colt material (e.g., emboli and/or thrombi) within a blood vessel of a human patient. In particular, some embodiments of the present technology relate to expandable devices for engaging and removing clot material.


BACKGROUND

Thromboembolic events are characterized by an occlusion of a blood vessel. Thromboembolic disorders, such as stroke, pulmonary embolism, heart attack, peripheral thrombosis, atherosclerosis, and the like, affect many people. These disorders are a major cause of morbidity and mortality.


When an artery is occluded by a clot, tissue ischemia develops. The ischemia will progress to tissue infarction if the occlusion persists. However, infarction does not develop or is greatly limited if the flow of blood is reestablished rapidly. Failure to reestablish blood flow can accordingly lead to the loss of limb, angina pectoris, myocardial infarction, stroke, or even death.


In the venous circulation, occlusive material can also cause serious harm. Blood clots can develop in the large veins of the legs and pelvis, a common condition known as deep venous thrombosis (DVT). DVT commonly occurs where there is a propensity for stagnated blood (e.g., long distance air travel, immobility, etc.) and clotting (e.g., cancer, recent surgery, such as orthopedic surgery, etc.). DVT can obstruct drainage of venous blood from the legs leading to swelling, ulcers, pain and infection. DVT can also create a reservoir in which blood clots can collect and then travel to other parts of the body including the heart, lungs, brain (stroke), abdominal organs, and/or extremities.


In the pulmonary circulation, the undesirable material can cause harm by obstructing pulmonary arteries—a condition known as pulmonary embolism. If the obstruction is upstream, in the main or large branch pulmonary arteries, it can severely compromise total blood flow within the lungs, and therefore the entire body. This can result in low blood pressure and shock. If the obstruction is downstream, in large to medium pulmonary artery branches, it can prevent a significant portion of the lung from participating in the exchange of gases to the blood resulting in low blood oxygen and buildup of blood carbon dioxide.


There are many existing techniques to reestablish blood flow through an occluded vessel. Embolectomies, for example, are a surgical technique involving incising a blood vessel and placing a balloon-tipped device (such as the Fogarty catheter) at the location of the occlusion. The balloon is then inflated at a point beyond the clot and used to withdraw the obstructing material back to the point of incision. The obstructing material is then removed by the surgeon. Although such surgical techniques have been useful, exposing a patient to surgery may be traumatic and best avoided when possible. Additionally, the use of a Fogarty catheter may be problematic due to the possible risk of damaging the interior lining of the vessel as the catheter is being withdrawn.


Percutaneous methods are also utilized for reestablishing blood flow. A common percutaneous technique is referred to as balloon angioplasty where a balloon-tipped catheter is introduced to a blood vessel (e.g., typically through an introducing catheter). The balloon-tipped catheter is then advanced to the point of the occlusion and inflated to dilate the stenosis. Balloon angioplasty is appropriate for treating vessel stenosis, but it is generally not effective for treating acute thromboembolisms as none of the occlusive material is removed and restenosis regularly occurs after dilation. Another percutaneous technique involves placing a catheter near the clot and infusing streptokinase, urokinase, or other thrombolytic agents to dissolve the clot. Unfortunately, thrombolysis typically takes hours to days to be successful. Additionally, thrombolytic agents can cause hemorrhage, and in many patients the thrombolytic agents cannot be used at all.


Various devices exist for performing a thrombectomy or removing other foreign material. However, such devices have been found to have structures which are either highly complex, cause trauma to the treatment vessel, or lack the ability to be appropriately fixed against the vessel. Furthermore, many of the devices have highly complex structures that lead to manufacturing and quality control difficulties as well as delivery issues when passing through tortuous or small diameter catheters. Less complex devices may allow the user to pull through the clot, particularly with inexperienced users, and such devices may not completely capture and/or collect all of the clot material.


Thus, there exists a need for improved systems and methods for embolic extraction.





BRIEF DESCRIPTION OF THE DRAWINGS

Many aspects of the present technology can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale. Instead, emphasis is placed on illustrating clearly the principles of the present disclosure.



FIGS. 1A and 1B are side views of a clot treatment system in a pre-deployed configuration and a deployed configuration, respectively, configured in accordance with embodiments of the present technology.



FIG. 1C is an enlarged perspective view of a distal portion of the clot treatment system shown in FIG. 1B configured in accordance with an embodiment of the present technology.



FIGS. 2A-2C are a side view, a proximally-facing perspective view, and a distally-facing perspective view, respectively, of a clot treatment device of the clot treatment system of FIGS. 1A-1C configured in accordance with embodiments of the present technology.



FIG. 3 is a flow diagram of a process or method for operating the clot treatment system to remove clot material from within a blood vessel of a human patient in accordance with an embodiment of the present technology.



FIGS. 4A-4F are schematic illustrations of a distal portion of the clot treatment system during a procedure to remove clot material from a blood vessel of a human patient in accordance with embodiments of the present technology.





DETAILED DESCRIPTION

The present technology is generally directed to systems, devices, and methods for removing clot material from a blood vessel of a human patient. In some embodiments, a clot removal system can include a delivery catheter and a clot treatment device. The clot treatment device can include a plurality of interconnected struts forming a unitary structure that is movable between a compressed configuration and an expanded configuration. In the expanded configuration, the unitary structure can include (i) a proximal connection region, (ii) a proximal conical region extending from the proximal connection region, (iii) a cylindrical region extending from the proximal conical region, (iv) a distal conical region extending from the cylindrical region, and (v) a distal connection region extending from the distal conical region. In some embodiments, a first portion of the struts form first cells in the proximal conical region, and a second portion of the struts form second cells in the distal conical region that are smaller than the first cells.


In some embodiments, the system further includes a handle configured to be gripped by an operator, and a first shaft coupled between the handle and the proximal connection region of the clot treatment device. The clot treatment device can be maintained in the compressed configuration within a lumen of the delivery catheter and near a distal terminus of the delivery catheter. To move the clot treatment device to the expanded configuration, the operator can move the handle to advance the first shaft to thereby advance the clot treatment device past the distal terminus and out of the lumen of the delivery catheter. When the clot treatment device is no longer constrained by the delivery catheter, the clot treatment device can expand (e.g., self-expand) to the expanded configuration. In some embodiments, the system further includes a second shaft extending at least partially through the first shaft and coupled to the distal connection region of the clot treatment device. Relative movement between the first and second shafts can allow the clot treatment device to lengthen/shorten and to correspondingly radially expand/compress.


During a procedure to remove clot material from a blood vessel of a human patient, the clot treatment device can be expanded distal of the clot material within the blood vessel, and then retracted proximally into the clot material to capture/disrupt the clot material. In one aspect of the present technology, the larger first cells of the clot treatment device are configured to receive the clot material therethrough as the clot treatment device is pulled against the clot material, and the smaller second cells of the clot treatment device are configured to retain the clot material within the clot treatment device. In another aspect of the present technology, the clot treatment device has sufficient radial stiffness (e.g., at the cylindrical region) to inhibit the clot treatment device from slipping (e.g., not engaging) the clot material when the clot treatment device is pulled against the clot material. Accordingly, the clot treatment device can be used to capture/disrupt adhered, organized, and/or chronic clots that would otherwise be difficult to remove.


Although many of the embodiments are described below with respect to systems, devices, and methods for treating a pulmonary embolism, other applications and other embodiments in addition to those described herein are within the scope of the technology (e.g., intravascular procedures other than the treatment of emboli, intravascular procedures for treating cerebral embolism, intravascular procedures for treating deep vein thrombosis (DVT), etc.). Additionally, several other embodiments of the technology can have different configurations, states, components, or procedures than those described herein. Moreover, it will be appreciated that specific elements, substructures, advantages, uses, and/or other features of the embodiments described with reference to FIGS. 1-4F can be suitably interchanged, substituted or otherwise configured with one another in accordance with additional embodiments of the present technology. Furthermore, suitable elements of the embodiments described with reference to FIGS. 1-4F can be used as standalone and/or self-contained devices. A person of ordinary skill in the art, therefore, will accordingly understand that the technology can have other embodiments with additional elements, or the technology can have other embodiments without several of the features shown and described below with reference to FIGS. 1-4F.


With regard to the terms “distal” and “proximal” within this description, unless otherwise specified, the terms can reference a relative position of the portions of a catheter subsystem with reference to an operator and/or a location in the vasculature. Also, as used herein, the designations “rearward,” “forward,” “upward,” “downward,” etc. are not meant to limit the referenced component to use in a specific orientation. It will be appreciated that such designations refer to the orientation of the referenced component as illustrated in the Figures; the systems and devices of the present technology can be used in any orientation suitable to the user.



FIGS. 1A and 1B are side views of a clot treatment or clot removal system 100 (“system 100”) configured in accordance with embodiments of the present technology. The system 100 is in a constrained/pre-deployment configuration in FIG. 1A, and the system 100 is in an expanded/deployed configuration in FIG. 1B. Referring to FIGS. 1A and 1B together, in the illustrated embodiment the system 100 includes a delivery catheter 102 (e.g., a tube, a shaft, etc.; which can also be referred to herein as an outer shaft) defining a lumen and having a proximal end portion 103a and a distal end portion 103b. The proximal end portion 103a of the delivery catheter 102 is coupled to a hub 110, such as a sealable hub, valve, etc. The lumen of the delivery catheter 102 can be fluidly coupled to a port assembly 112 via the hub 110.


In the illustrated embodiment, the port assembly 112 includes a fluid control device 114 fluidly coupled between (i) a port connector 116 (e.g., a Luer connector/fitting) and (ii) a tubing section 118 coupled to the hub 110 (e.g., to a branch or side port of the hub 110). The fluid control device 114 is actuatable to fluidly connect the lumen of the delivery catheter 102 to the port connector 116. In the illustrated embodiment, the fluid control device 114 is a stopcock while, in other embodiments, the fluid control device 114 can be a clamp, valve, and/or other suitable fluid control device. During a clot removal procedure using the system 100, various components (e.g., syringes, vacuum sources, etc.) can be coupled to the port connector 116 to remove fluid from and/or inject fluid into the lumen of the delivery catheter 102. For example, in some embodiments a syringe or other pressure source can be coupled to the port connector 116 and used to draw a vacuum while the fluid control device 114 is closed, and the fluid control device 114 can then be opened to instantaneously or nearly instantaneously apply the vacuum to the lumen of the delivery catheter 102 (e.g., to generate suction at the distal portion 103b for removing clot material). In other embodiments, a constant vacuum source (e.g., a pump) can be coupled to the port assembly 112 to provide constant aspiration of the lumen of the delivery catheter 102. In some embodiments, flushing fluid (e.g., saline) can be injected through the port assembly 112 to flush the lumen of the delivery catheter 102.


In the illustrated embodiment, the system 100 further includes an intermediate shaft 104 (e.g., a catheter, tube, etc.) extending at least partially through the lumen of the delivery catheter 102 and defining a lumen, and an inner shaft 106 (e.g., a catheter, tube, etc.) extending at least partially through the lumen of the intermediate shaft 104. Accordingly, in some embodiments the delivery catheter 102, the intermediate shaft 104, and the inner shaft 106 are coaxially aligned/arranged. The system 100 further includes a clot treatment device 130 coupled to the intermediate shaft 104 and the inner shaft 106. The delivery catheter 102, the intermediate shaft 104, the inner shaft 106, and the clot treatment device 130 can collectively be referred to as a treatment portion 111 (e.g., an insertion portion) of the system 100. As described in greater detail below with reference to FIGS. 3-4F, the treatment portion 111 is configured to be inserted through a guide catheter to position the clot treatment device 130 at a treatment site during a clot removal procedure.


As described in greater detail below with reference to FIGS. 2A-2C, the clot treatment device 130 can be a self-expanding unitary structure comprising a plurality of interconnected struts. In the pre-deployment configuration shown in FIG. 1A, the clot treatment device 130 is constrained within the delivery catheter 102 and thus obscured. In the deployed configuration shown in FIG. 1B, the clot treatment device 130 extends past the distal end portion 103b of the delivery catheter 102 (e.g., a distal terminus of the delivery catheter 102) and is radially expanded.



FIG. 1C is an enlarged perspective view of a distal portion of the system 100 shown in FIG. 1B configured in accordance with an embodiment of the present technology. In the illustrated embodiment, the intermediate shaft 104 includes a distal end portion 105b coupled to a proximal portion 131a of the clot treatment device 130. In some embodiments, the proximal portion 131a of the clot treatment device 130 includes a plurality of struts that are gathered together and secured to the distal end portion 105b of the intermediate shaft 104. For example, the struts at the proximal portion 131a of the clot treatment device 130 can be secured to the outer surface of the intermediate shaft 104 via adhesives, fasteners, a hub or other device, etc. The inner shaft 106 includes a distal end portion 107 coupled to a distal portion 131b of the clot treatment device 130. In some embodiments, the distal portion 131b of the clot treatment device 130 includes a plurality of struts that are gathered together and secured to the distal end portion 107 of the inner shaft 106 via a friction fit, pressure fit, etc., between the inner shaft 106 and a distal tip 108 (e.g., an atraumatic tip). In other embodiments, the struts at the distal portion 131b of the clot treatment device 130 can be secured to the outer surface of the inner shaft 106 via adhesives, fasteners, a hub or other device, etc.


Referring again to FIGS. 1A and 1B together, the intermediate shaft 104 includes a proximal end portion 105a coupled to the handle 120 (e.g., to a distal portion of the handle 120) to operably couple the handle 120 to the clot treatment device 130. Accordingly, the intermediate shaft 104 extends between and operably couples the handle 120 and the clot treatment device 130. In some embodiments, a proximal end portion of the inner shaft 106 (obscured in FIGS. 1A and 1B) is not coupled to any portion of the system 100 and floats within the lumen of the intermediate shaft 104. In one aspect of the present technology, this arrangement allows the inner shaft 106 to move relative to the intermediate shaft 104 in response to external forces on the clot treatment device 130, thereby allowing the clot treatment device 130 to elongate/shorten longitudinally and to correspondingly radially compress/expand. In other embodiments, the proximal end portion of the inner shaft 106 can be coupled to an actuation mechanism 122 (shown in dashed lines in FIGS. 1A and 1B) of the handle 120. The actuation mechanism 122 can be configured to drive the inner shaft 106 proximally and/or distally to shorten and/or elongate, respectively, the clot treatment device 130. More specifically, in some embodiments distal movement of the actuation mechanism 122 relative to the handle 120 can move the inner shaft 106 distally relative to the intermediate shaft 104 to lengthen and radially compress the clot treatment device 130, while proximal movement of the actuation mechanism 122 relative to the handle 120 can move the inner shaft 106 proximally relative to the intermediate shaft 104 to shorten and radially expand the clot treatment device 130.


In the illustrated embodiment, the handle 120 further includes a proximal hub 124, such as a Luer hub, configured to receive a guidewire (not shown) therethrough. The handle 120, the inner shaft 106, and the tip 108 can together define a lumen for receiving the guidewire therethrough. In some embodiments, the guidewire can have a diameter of about 0.035 inch, about 0.018 inch, less than about 0.1 inch, less than about 0.05 inch, etc. In some embodiments, the handle 120 further includes a lock feature 126 such as, for example, a spinlock or a push-in-and-turn lock. The lock feature 126 is configured to selectively engage (e.g., lockingly engage) with a mating feature 115 of the hub 110. Locking the handle 120 to the hub 110 via the lock feature 126 and the mating feature 115 secures the position of the intermediate shaft 104 relative to the delivery catheter 102. In the illustrated embodiment, the intermediate shaft 104 is longer than the delivery catheter 102 such that a portion of the intermediate shaft 104 and the clot treatment device 130 extend distally from the distal end portion 103b of the delivery catheter 102 when the handle 120 is lockingly engaged with the hub 110.


To deploy the clot treatment device 130 from the pre-deployment configuration (FIG. 1A) to the deployed configuration (FIG. 1B), an operator can move the handle 120 distally toward the hub 110 and/or can move the hub 110 toward the handle 120. This movement advances the intermediate shaft 104 distally through the delivery catheter 102 and pushes the clot treatment device 130 distally out of the delivery catheter 102. The clot treatment device 130 can self-expand as it is released from the lumen of the delivery catheter 102. When the handle 120 abuts the hub 110, the operator can actuate the lock feature 126 to secure the position of the intermediate shaft 104 relative to the delivery catheter 102 to, for example, maintain the clot treatment device 130 in the deployed configuration.


In some embodiments, proximal movement of the handle 120 and/or distal movement of the hub 110 (e.g., from the position shown in FIG. 1B to the position shown in FIG. 1A) can retract the clot treatment device 130 back into the delivery catheter 102. That is, in some embodiments the clot treatment device 130 can be resheathed within the delivery catheter 102. In such embodiments, the clot treatment device 130 can be repeatedly expanded and then retracted and compressed into the delivery catheter 102. In some embodiments, the tip 108 is configured (e.g., sized and shaped) to abut the distal end portion 103b of the delivery catheter 102 in the pre-deployment configuration (FIG. 1A). This can inhibit or even prevent the clot treatment device 130 from being pulled fully through the delivery catheter 102 and, in some embodiments, can substantially seal the lumen of the delivery catheter 102. In other embodiments, the tip 108 is sized and shaped to allow the tip 108—and thus the entire clot treatment device 130—to be retracted through the delivery catheter 102.



FIGS. 2A-2C are a side view, a proximally-facing perspective view, and a distally-facing perspective view, respectively, of the clot treatment device 130 in the expanded configuration in accordance with embodiments of the present technology. Referring to FIGS. 2A-2C together, the clot treatment device 130 comprises a plurality of struts 240 that together define a plurality of first cells 250 (e.g., interstices, pores, openings, etc.) and a plurality of second cells 252. The struts 240 can have a variety of shapes and sizes and, in some embodiments, the struts 240 can have a thickness and/or diameter between about 0.0125-0.150 inch, between about 0.075-0.125 inch, between about 0.090-0.150 inch, and/or other dimensions. In general, the struts 240 together form a unitary structure that is configured to engage, capture, disrupt, and/or separate a portion of a thrombus (e.g., a vascular thrombus) from a blood vessel containing the thrombus.


In the illustrated embodiment, (i) the first cells 250 generally face proximally while the second cells 252 generally face distally, and (ii) the first cells 250 are larger than the second cells 252. As best seen in FIG. 2A, the clot treatment device 130 includes (i) a first region 242 including the proximal portion 131a, (ii) a second region 243 distal of the first region 242, (iii) a third (e.g., central) region 244 distal of the second region 243, (iv) a fourth region 245 distal of the third region 244, and (v) a fifth region 246 distal of the fourth region 245 and including the distal portion 131b. In the illustrated embodiment, the struts 240 are gathered together (e.g. positioned proximate one another) at the first and fifth regions 242, 246 to facilitate their connection to the intermediate and inner shafts 104, 106, respectively, as shown in FIG. 1C. The second region 243 can have a generally conical shape that tapers (e.g., radially narrows) in the proximal direction. Similarly, the fourth region 245 can have a generally conical shape that tapers in the distal direction. The third region 244 can have a generally tubular/cylindrical shape including, for example a generally flat outer strut surface/boundary 248. Moreover, in the illustrated embodiment the first and second regions 242, 243 have fewer of the struts 240 than the fourth and fifth regions 245, 246 to thereby define the larger first cells 250. Conversely, the fourth and fifth regions 245, 246 have more of the struts 240 than the first and second regions 242, 243 to thereby define the smaller second cells 252. The third region 244 can be a transition region in which the number of the struts 240 increases in the proximal direction (e.g., toward the fourth region 245) such that some of the first cells 250 abut some of the second cells 252 in the third region 244. In other embodiments, the first cells 250 can be formed only in the second region 243, can occupy the entire third region 244, can extend into the fourth region 245, etc.


In some embodiments, the clot treatment device 130 is made from a shape memory material such as a shape memory alloy and/or a shape memory polymer. For example, the clot treatment device 130 can comprise nitinol and/or a nitinol alloy. Similarly, the clot treatment device 130 can be made using a variety of techniques including welding, laser welding, cutting, laser cutting, expanding, etc. For example, in some embodiments the clot treatment device 130 can first be laser cut from a piece of nitinol (e.g., a nitinol tube), and then further shaped using a heat setting process such that the clot treatment device 130 has the illustrated shape in the expanded configuration. For example, as is known in the art of heat setting nitinol structures, a fixture, mandrel, or mold may be used to hold the clot treatment device 130 in its desired configuration, and then the clot treatment device 130 can be subjected to an appropriate heat treatment such that the struts 240 of the clot treatment device 130 assume or are otherwise shape-set to the outer contour of the mandrel or mold. The heat setting process may be performed in an oven or fluidized bed, as is well-known. Therefore, the heat setting process can impart a desired shape, geometry, bend, curve, serration, scallop, void, hole, etc., in the super-elastic and/or shape memory material or materials used to form the clot treatment device 130. Accordingly, the clot treatment device 130 may be radially constrained without plastic deformation and will self-expand on release of the radial constraint.


In general, the size of the clot treatment device 130 can be selected based on the size (e.g., diameter) of the blood vessel from which thrombus is to be extracted. In some embodiments, in a fully-expanded configuration unconstrained within a vessel, the clot treatment device 130 can have a length L (FIG. 2A) of between about 0.025-1.50 inches, between about 0.70-1.15 inches, etc. In some embodiments, in the fully-expanded position unconstrained within a vessel, the clot treatment device 130 can have a maximum diameter D (FIG. 2A; e.g., at the third region 244) of between about 0.025-1.5 inches, between about 0.71-1.34 inches, etc.


The clot treatment device 130 is configured (e.g., shaped, sized, angled, formed, etc.) to engage, disrupt, and/or capture clot material from within a blood vessel when the clot treatment device 130 is retracted through/against the clot material in the expanded configuration. For example, as described in greater detail below with reference to FIGS. 3-4F, the clot treatment device 130 can be withdrawn proximally through/against the clot material. In one aspect of the present technology, the larger first cells 250 are configured to receive the clot material therethrough as the clot treatment device 130 is pulled against the clot material, and the smaller second cells 252 (and associated struts 240) are configured to retain the clot material within the clot treatment device 130. In another aspect of the present technology, the clot treatment device 130 has sufficient radial stiffness (e.g., at the third region 244) to inhibit the clot treatment device 130 from slipping (e.g., not engaging) the clot material when the clot treatment device 130 is pulled against the clot material. Accordingly, the clot treatment device 130 can be used to capture/disrupt adhered, organized, and/or chronic clots. In some embodiments, portions of the struts 240 (e.g., at the second region 243) can be sharpened and/or can include a cutting element (e.g., a knife or knife edge) attached thereto or otherwise integrated with to further facilitate disruption/cutting of the clot material.



FIG. 3 is a flow diagram of a process or method 360 for operating the system 100 to remove clot material from within a blood vessel (e.g., a pulmonary blood vessel) of a patient (e.g., a human patient) in accordance with an embodiment the present technology. FIGS. 4A-4F are schematic illustrations of a distal portion of the system 100 inserted through a guide catheter 470 during a procedure to remove clot material PE from a blood vessel BV of a patient in accordance with embodiments of the present technology. Although some features of the method 360 are described in the context of the embodiments shown in FIGS. 4A-4F for the sake of illustration, one skilled in the art will readily understand that the method 360 can be carried out using other suitable systems and/or devices described herein.


With reference to FIGS. 3 and 4A, at block 361, the method 360 can include positioning a distal portion 471 of the guide catheter 470 proximate to the clot material PE within the blood vessel BV (e.g., at a treatment site). In the illustrated embodiment, a distal terminus of the guide catheter 470 is positioned proximate to a proximal portion of the clot material PE. However, in other embodiments the distal terminus of the guide catheter 470 can be positioned at least partially within the clot material PE, or the distal terminus of the guide catheter 470 can be positioned distal of the clot material PE. Access to the blood vessel BV can be achieved through the patient's vasculature, for example, via the femoral vein. In some embodiments, such as when the blood vessel BV is a pulmonary blood vessel, an introducer (e.g., a Y-connector with a hemostasis valve; not shown) is connected to the guide catheter 470 and can be partially inserted into the femoral vein. A guidewire 472 can be guided into the femoral vein through the introducer and navigated through the right atrium, the tricuspid valve, the right ventricle, the pulmonary valve, and into the main pulmonary artery. Depending on the location of the clot material PE, the guidewire 472 can be guided to one or more of the branches of the right pulmonary artery and/or the left pulmonary artery. In some embodiments, the guidewire 472 can be extended entirely or partially through the clot material PE. In other embodiments, the guidewire 472 can be extended to a location just proximal of the clot material PE. After positioning the guidewire 472, the guide catheter 470 can be placed over the guidewire 472 and advanced to the position proximate to the clot material PE as illustrated in FIG. 4A.


In some embodiments, a pressure source can be coupled to the guide catheter 470 and used to aspirate the lumen of the guide catheter 470 to, for example, generate suction (e.g., as indicated by arrows A) to suck/draw all or a portion of the clot material PE into the guide catheter 470. For example, in some embodiments a vacuum can be pre-charged (e.g., in a syringe fluidly coupled to the lumen of the guide catheter 470) and the vacuum can be applied to the lumen of the guide catheter 470 to instantaneously or nearly instantaneously generate suction at the distal portion 471 of the guide catheter 470 (e.g., to generate a suction pulse at the distal portion 471 of the guide catheter 470). Specific details of such methods and associated devices are disclosed in U.S. patent application Ser. No. 16/536,185, filed Aug. 8, 2019, and titled “SYSTEM FOR TREATING EMBOLISM AND ASSOCIATED DEVICES AND METHODS,” which is incorporated herein by reference in its entirety.


However, even where suction is applied to remove/dislodge the clot material PE from the blood vessel BV, the suction may not be enough to dislodge/disrupt all the clot material PE. For example, many chronic (e.g., organized) clots can strongly adhere to the walls of the blood vessel BV—making it difficult to remove them. In one aspect of the present technology, the system 100 can be inserted through the guide catheter 470 before, during, and/or after suction is applied via the guide catheter 470 to engage, disrupt, and/or capture the clot material PE—even where the clot material PE is strongly adhered within the blood vessel BV.


For example, with reference to FIGS. 3 and 4B, at block 362, the method 360 can include advancing the clot treatment device 130 (compressed within the delivery catheter 102 and thus obscured in FIG. 4B) through the guide catheter 470 to proximate the clot material PE. More specifically, the treatment portion 111 of the system 100 can be advanced through the guide catheter 470 in the compressed pre-deployment configuration until the tip 108 is positioned (i) distal of the distal portion 471 of the guide catheter 470 and (ii) distal of the clot material PE within the blood vessel BV. In other embodiments, the tip 108 can be positioned within the clot material PE. In some embodiments, the treatment portion 111 can be advanced over the guidewire 472 while, in other embodiments, the guidewire 472 can be omitted.


With reference to FIGS. 3 and 4C, at block 363, the method 360 can include moving the clot treatment device 130 from the compressed pre-deployment configuration to the expanded deployed configuration such that the clot treatment device 130 is expanded distal and/or partially within the clot material PE. For example, as described in detail above with reference to FIGS. 1A and 1B, an operator of the system 100 can advance the handle 120 distally toward the hub 110 and/or retract the hub 110 toward the handle 120 to move the intermediate shaft 104 relative to the delivery catheter 102 to advance the clot treatment device 130 out of the delivery catheter 102, thereby allowing the clot treatment device 130 to expand (e.g., self-expand) within the blood vessel BV. In the illustrated embodiment, the clot treatment device 130 (e.g., the outer strut surface 248 of the third region 244) contacts (e.g., engages, apposes, etc.) the wall of the blood vessel BV. In some embodiments, the clot treatment device 130 is oversized relative to the blood vessel BV such that the clot treatment device 130 exerts a radially outward force on the wall of the blood vessel BV. In other embodiments, the clot treatment device 130 can be sized such that it does not contact the walls of the blood vessel BV.


With reference to FIGS. 3 and 4D, at block 364, the method 360 can include retracting the clot treatment device 130 proximally (e.g., in the direction of arrow B) into/toward the clot material PE. More specifically, with reference to FIGS. 1A and 1B, the operator can pull the entire system 100 proximally (e.g., by gripping the hub 110) to retract the treatment portion 111 through the lumen of the guide catheter 470. As the clot treatment device 130 is retracted, the clot treatment device 130 engages the clot material PE to capture/disrupt the clot material PE. For example, the clot material PE can enter through the first cells 250 (FIGS. 2A-2C) and be retained within the clot treatment device 130 by the smaller second cells 252 (FIGS. 2A-2C). In one aspect of the present technology, the clot treatment device 130 can shear the clot material PE from the wall of the blood vessel BV even where the clot material PE is strongly adhered to the wall of the blood vessel BV.


In some embodiments, where the inner shaft 106 floats within the lumen of the intermediate shaft 104, the length L (FIG. 2A) of the clot treatment device 130 can increase as the clot treatment device 130 is pulled into/against the clot material PE and the intermediate shaft 104 moves proximally relative to the inner shaft 106. In other embodiments, where the system 100 includes the actuation mechanism 122, the operator can actuate the actuation mechanism 122 to increase the longitudinal and/or radial stiffness of the clot treatment device 130 by locking or substantially locking the relative position of the intermediate and inner shafts 104, 106.


With reference to FIGS. 3 and 4E, at block 365, the method 360 can include retracting the clot treatment device 130 and the captured clot material PE into the lumen of the guide catheter 470. In some embodiments, the clot treatment device 130 can be fully removed from the guide catheter 470. In some embodiments, if any of the clot material PE remains in the blood vessel BV, the clot treatment device 130 can be cleaned and blocks 362-365 can be repeated to capture the remaining clot material PE. Alternatively, a new clot treatment device 130 can be reinserted through the guide catheter 470 to capture the remaining clot material PE. In some embodiments, the clot treatment device 130 can break apart the clot material PE without necessarily capturing the clot material PE and, after or during retraction of the clot treatment device 130, aspiration can be applied to the guide catheter 470 to suck the remaining clot material PE into the guide catheter 470. Finally, with reference to FIGS. 3 and 4F, at block 366, the method 360 can include removing the guide catheter 470 from the blood vessel BV and from the patient after a sufficient portion of the clot material is removed from the patient.


Several aspects of the present technology are set forth in the following additional examples:


1. A clot treatment system, comprising:

    • an outer catheter defining a lumen;
    • an inner catheter positioned at least partially in the lumen of the outer catheter; and a clot treatment device including a plurality of interconnected struts forming a unitary structure movable between a compressed configuration and an expanded configuration, wherein in the expanded configuration the unitary structure includes—
      • a proximal connection region coupled to the outer catheter;
      • a proximal conical region extending from the proximal connection region, wherein a first portion of the struts form first cells in the proximal conical region;
      • a cylindrical region extending from the proximal conical region;
      • a distal conical region extending from the cylindrical region, wherein a second portion of the struts from second cells in the distal conical region, and wherein the second cells are smaller than the first cells; and
      • a distal connection region extending from the distal conical region and coupled to the inner catheter.


2. The clot treatment system of example 1 wherein the inner catheter has (a) a distal end portion coupled to the distal connection region of the clot treatment device and (b) a proximal end portion configured to float within the lumen of the outer catheter.


3. The clot treatment system of example 1 or example 2 wherein the inner and outer catheters are configured to receive a guidewire therethrough.


4. The clot treatment system of any one of examples 1-3, further comprising a handle coupled to a proximal end portion of the outer catheter, wherein the handle includes an actuation mechanism coupled to a proximal end portion of the inner catheter, and wherein actuation of the actuation mechanism is configured to translate the inner catheter relative to the outer catheter to longitudinally compress or longitudinally elongate the clot treatment device.


5. The clot treatment system of any one of examples 1-4, further comprising:

    • a delivery catheter defining a lumen; and
    • a handle coupled to a proximal end portion of the outer catheter and movable between a first position and a second position relative to the delivery catheter, wherein—
      • in the first position, the clot treatment device is constrained within the lumen of the delivery catheter in the compressed configuration, and
      • in the second position, the clot treatment device is positioned distal of the lumen in the expanded configuration.


6. The clot treatment system of example 5, further comprising a hub coupled to a proximal end portion of the delivery catheter, wherein the handle includes a lock feature configured to secure the handle to the hub in the second position.


7. The clot treatment system of example 5 or example 6 wherein the handle, the delivery catheter, the outer catheter, and the inner catheter are configured to receive a guidewire therethrough.


8. The clot treatment system of any one of examples 1-7 wherein, in the expanded configuration, the cylindrical region has a diameter of between about 0.71 inch to about 1.34 inches.


9. The clot treatment system of any one of examples 1-8 wherein the struts of the clot treatment device are configured to self-expand from the compressed configuration to the expanded configuration when unconstrained.


10. The clot treatment system of any one of examples 1-9 wherein the struts of the clot treatment device include a shape memory material.


11. The clot treatment system of any one of examples 1-10 wherein the unitary structure includes (a) a first number of the struts in the proximal conical region and (b) a second number of the struts in the distal conical region that is greater than the first number of struts.


12. A method of clot removal, the method comprising:

    • positioning a distal portion of a guide catheter proximate to clot material within a blood vessel of a human patient;
    • advancing a clot treatment device through the guide catheter to proximate the clot material;
    • expanding the clot treatment within the blood vessel distal of the clot material, wherein the clot treatment device includes a plurality of interconnected struts forming a unitary structure having a proximal portion and a distal portion, wherein the struts form a plurality of first cells in the proximal portion and a plurality of second cells in the distal portion, and wherein the first cells are larger than the second cells;
    • generating suction at the distal portion of the guide catheter; and
    • proximally retracting the clot treatment device through the clot material.


13. The method of example 12 wherein advancing the clot treatment device through the guide catheter includes advancing the clot treatment device over a guidewire.


14. The method of example 12 or example 13 wherein the proximal portion of the unitary structure is coupled to an outer catheter extending at least partially through the guide catheter, and wherein the distal portion of the unitary structure is coupled to an inner catheter extending at least partially through the outer catheter.


15. The method of example 14 wherein advancing the clot treatment device through the guide catheter includes advancing the clot treatment device over a guidewire extending through the guide, outer, and inner catheters.


16. The method of any one of examples 12-15 wherein generating suction at the distal portion of the guide catheter includes generating suction, before proximally retracting the clot treatment device, to aspirate a first portion of the clot material into the guide catheter.


17. The method of example 16 wherein proximally retracting the clot treatment device includes proximally retracting the clot treatment device through a second portion of the clot material remaining in the blood vessel to capture the second portion of the clot material.


18. The method of any one of examples 12-17 wherein proximally retracting the clot treatment device through the clot material includes capturing at least a portion of the clot material, and wherein the method further comprises retracting the clot treatment device and the captured clot material into the guide catheter.


19. A clot treatment system, comprising:

    • an outer shaft defining a lumen;
    • an inner shaft positioned at least partially in the lumen of the outer shaft; and
    • a plurality of interconnected struts forming a unitary structure having a proximal portion and a distal portion, wherein the proximal portion is coupled to the outer shaft, wherein the distal portion is coupled to the inner shaft, and wherein the struts form a plurality of first cells in the proximal portion and a plurality of second cells in the distal portion, and wherein the first cells are larger than the second cells.


20. The clot treatment system of example 12 wherein the outer shaft and the inner shaft are configured to receive a guidewire therethrough.


21. A clot treatment device, comprising:

    • a plurality of interconnected struts forming a unitary structure movable between a compressed configuration and an expanded configuration, wherein in the expanded configuration the unitary structure includes—
      • a proximal connection region;
      • a proximal conical region extending from the proximal connection region, wherein a first portion of the struts form first cells in the proximal conical region;
      • a cylindrical region extending from the proximal conical region;
      • a distal conical region extending from the cylindrical region, wherein a second portion of the struts from second cells in the distal conical region, and wherein the second cells are smaller than the first cells; and
      • a distal connection region extending from the distal conical region.


22. The clot treatment device of example 21, further comprising:

    • a first shaft coupled to the proximal connection region and defining a lumen; and
    • a second shaft coupled to the distal connection region and extending at least partially through the lumen of the first shaft.


23. The clot treatment device of example 21 or example 22 wherein the second shaft has (a) a distal end portion coupled to the distal connection region and (b) a proximal end portion configured to float within the lumen of the first shaft.


24. The clot treatment device of any one of examples 21-23 wherein the struts are configured to self-expand from the compressed configuration to the expanded configuration when unconstrained.


25. The clot treatment device of any one of examples 21-24 wherein the struts are made from a shape memory material.


26. A clot treatment device, comprising:

    • a plurality of interconnected struts forming a unitary structure having a proximal portion and a distal portion, wherein the struts form a plurality of first cells in the proximal portion and a plurality of second cells in the distal portion, and wherein the first cells are larger than the second cells.


The above detailed descriptions of embodiments of the technology are not intended to be exhaustive or to limit the technology to the precise form disclosed above. Although specific embodiments of, and examples for, the technology are described above for illustrative purposes, various equivalent modifications are possible within the scope of the technology as those skilled in the relevant art will recognize. For example, although steps are presented in a given order, alternative embodiments may perform steps in a different order. The various embodiments described herein may also be combined to provide further embodiments.


From the foregoing, it will be appreciated that specific embodiments of the technology have been described herein for purposes of illustration, but well-known structures and functions have not been shown or described in detail to avoid unnecessarily obscuring the description of the embodiments of the technology. Where the context permits, singular or plural terms may also include the plural or singular term, respectively.


Moreover, unless the word “or” is expressly limited to mean only a single item exclusive from the other items in reference to a list of two or more items, then the use of “or” in such a list is to be interpreted as including (a) any single item in the list, (b) all of the items in the list, or (c) any combination of the items in the list. Additionally, the term “comprising” is used throughout to mean including at least the recited feature(s) such that any greater number of the same feature and/or additional types of other features are not precluded. It will also be appreciated that specific embodiments have been described herein for purposes of illustration, but that various modifications may be made without deviating from the technology. Further, while advantages associated with some embodiments of the technology have been described in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the technology. Accordingly, the disclosure and associated technology can encompass other embodiments not expressly shown or described herein.

Claims
  • 1. A method for the intravascular treatment of clot material from within a blood vessel of a human patient, the method comprising: positioning a distal portion of an aspiration catheter proximate to the clot material within the blood vessel, wherein the aspiration catheter defines an aspiration lumen;generating vacuum pressure within a barrel of a syringe and storing the vacuum pressure within the barrel;applying the vacuum pressure to the aspiration lumen to aspirate at least a first portion of the clot material into the aspiration lumen by opening a valve fluidically coupled to the barrel and the aspiration lumen;determining that a second portion of the clot material remains within the blood vessel;advancing a clot treatment device having an expandable member through the aspiration lumen such that the clot treatment device is positioned at least partially distal to the second portion of the clot material;expanding the expandable member of the clot treatment device within the blood vessel distal of the clot material, wherein the expandable member includes a plurality of interconnected struts forming a unitary structure having a proximal region and a distal region, wherein the struts form a plurality of first cells in the proximal region and a plurality of second cells in the distal region, and wherein the first cells are larger than the second cells; andproximally retracting the expandable member through the second portion of the clot material to capture and/or disrupt the second portion of the clot material.
  • 2. The method of claim 1, further comprising, after proximally retracting the expandable member: generating additional vacuum pressure with the barrel of the syringe;applying the additional vacuum pressure to the aspiration lumen to aspirate a third portion of the clot material into the aspiration lumen.
  • 3. The method of claim 1 wherein determining that the second portion of the clot material remains within the blood vessel includes determining that the clot material comprises chronic clot material.
  • 4. The method of claim 1 wherein determining that the second portion of the clot material remains within the blood vessel includes determining that the clot material comprises organized clot material.
  • 5. The method of claim 1 wherein advancing the clot treatment device through the aspiration catheter includes advancing the clot treatment device system over a guidewire.
  • 6. The method of claim 1 wherein (a) opening of the valve fluidly connects the barrel of the syringe to the aspiration lumen and (b) closing of the valve fluidly disconnects the barrel of the syringe from the aspiration lumen.
  • 7. The method of claim 6 wherein generating the vacuum pressure within the barrel of the syringe includes generating the vacuum pressure within the barrel while the valve is closed.
  • 8. The method of claim 7 wherein the syringe is a vacuum-pressure locking syringe.
  • 9. The method of claim 1 wherein the syringe is a vacuum-pressure locking syringe.
  • 10. The method of claim 1 wherein expanding the expandable member of the clot treatment device includes expanding the expandable member to substantially a diameter of the blood vessel.
  • 11. The method of claim 1 wherein the advancing the clot treatment device through the aspiration lumen includes advancing the clot treatment device such that the expandable member is positioned entirely distal to the second portion of the clot material.
  • 12. The method of claim 1 wherein the proximal region of the clot expandable member has a tapered shape that increases in diameter in a direction toward the distal region of the expandable member.
  • 13. The method of claim 12 wherein the distal region of the clot expandable member is generally cylindrical.
  • 14. The method of claim 13 wherein expanding the clot treatment device includes expanding the expandable member at least partially radially away from a longitudinal axis of the expandable member, and wherein the wherein the unitary structure of the expandable member further comprises: a proximal connection region extending proximally from the proximal region, wherein individual ones of the struts at the proximal connection region (a) extend generally parallel to the longitudinal axis, (b) are positioned circumferentially about the longitudinal axis, and (c) include a proximal terminus;a distal conical region extending distally from distal region; anda distal connection region extending distally from the distal conical region, wherein individual ones of the struts at the distal connection region (a) extend generally parallel to the longitudinal axis, (b) are positioned circumferentially about the longitudinal axis, and (c) include a distal terminus.
  • 15. The method of claim 14 wherein the struts at the proximal connection region are secured to a clot treatment catheter of the clot treatment device, and wherein the struts at the distal connection region are secured to a distal tip of the clot treatment device.
  • 16. The method of claim 1 wherein the clot material comprises a pulmonary embolism.
  • 17. The method of claim 1 wherein the clot material comprises a deep vein thrombosis.
  • 18. A method for the intravascular treatment of chronic clot material from within a blood vessel of a human patient, the method comprising: positioning a distal portion of an aspiration catheter proximate to the clot material within the blood vessel, wherein the aspiration catheter defines an aspiration lumen;coupling a syringe to the aspiration lumen via a fluid control device, wherein (a) opening of the fluid control device fluidly connects the syringe to the aspiration lumen and (b) closing of the fluid control device fluidly disconnects the syringe from the aspiration lumen;generating vacuum pressure with the syringe while the fluid control device is closed;opening the fluid control device to apply the vacuum pressure to the aspiration lumen to aspirate a first portion of the chronic clot material into the aspiration lumen;advancing a clot treatment device having an expandable member through the aspiration lumen such that the expandable member is positioned at least partially distal to a second portion of the clot material remaining within the blood vessel after the aspiration;expanding the expandable member of the clot treatment device within the blood vessel distal of the clot material, wherein the expandable member includes a plurality of interconnected struts forming a unitary structure having a proximal region and a distal region, wherein the struts form a plurality of first cells in the proximal region and a plurality of second cells in the distal region, and wherein the first cells are larger than the second cells; andproximally retracting the expandable member through the second portion of the clot material to capture and/or disrupt the second portion of the clot material.
  • 19. The method of claim 18, further comprising, after proximally retracting the expandable member: generating additional vacuum pressure with the syringe while the fluid control device is closed; andopening the fluid control device to apply the additional vacuum pressure to the aspiration lumen to aspirate a third portion of the clot material remaining within the blood vessel after proximally retracting the expandable member into the aspiration lumen.
  • 20. The method of claim 18 wherein expanding the expandable member of the clot treatment device includes expanding the expandable member to a diameter of the blood vessel, and wherein the distal region of the expandable member is generally cylindrical.
  • 21. The method of claim 18 wherein the syringe is a vacuum-pressure locking syringe.
  • 22. A method for the intravascular treatment of clot material from within a blood vessel of a human patient, the method comprising: positioning a distal portion of an aspiration catheter proximate to the clot material within the blood vessel, wherein the aspiration catheter defines an aspiration lumen;generating vacuum pressure within a barrel of a syringe and storing the vacuum pressure within the barrel;applying the vacuum pressure to the aspiration lumen to aspirate at least a first portion of the clot material into the aspiration lumen by opening a valve fluidically coupled to the barrel and the aspiration lumen;determining that a second portion of the clot material remains within the blood vessel;advancing a clot treatment device having an expandable member through the aspiration lumen such that the clot treatment device is positioned at least partially distal to the second portion of the clot material;expanding the expandable member of the clot treatment device within the blood vessel distal of the clot material, wherein the expandable member includes a plurality of interconnected struts forming a unitary structure having a conical region and cylindrical region distal of the conical region, wherein the struts form a plurality of first cells in the conical region and a plurality of second cells in the cylindrical region, and wherein the first cells are larger than the second cells; andproximally retracting the expandable member through the second portion of the clot material to capture and/or disrupt the second portion of the clot material.
CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation of U.S. patent application Ser. No. 17/072,909, filed Oct. 16, 2020, titled “SYSTEMS, DEVICES, AND METHODS FOR TREATING VASCULAR OCCLUSIONS,” which claims the benefit of U.S. Provisional Patent Application No. 62/916,044, filed Oct. 16, 2019, and titled “SYSTEMS, DEVICES, AND METHODS FOR TREATING VASCULAR OCCLUSIONS,” each of which is incorporated herein by reference in its entirety.

US Referenced Citations (876)
Number Name Date Kind
1101890 Tunstead Jun 1914 A
2784717 Thompson Mar 1957 A
2846179 Monckton Aug 1958 A
2955592 Maclean Oct 1960 A
3088363 Sparks May 1963 A
3197173 Taubenheim Jul 1965 A
3416531 Edwards Dec 1968 A
3435826 Fogarty Apr 1969 A
3438607 Williams et al. Apr 1969 A
3515137 Santomieri Jun 1970 A
3675657 Gauthier Jul 1972 A
3860006 Patel Jan 1975 A
3892161 Sokol Jul 1975 A
3923065 Nozick et al. Dec 1975 A
4030503 Clark, III Jun 1977 A
4034642 Iannucci et al. Jul 1977 A
4222380 Terayama Sep 1980 A
4243040 Beecher Jan 1981 A
4287808 Leonard et al. Sep 1981 A
4324262 Hall Apr 1982 A
4393872 Reznik et al. Jul 1983 A
4401107 Harber et al. Aug 1983 A
4469100 Hardwick Sep 1984 A
4523738 Raftis et al. Jun 1985 A
4551862 Haber Nov 1985 A
4604094 Shook Aug 1986 A
4611594 Grayhack et al. Sep 1986 A
4634421 Hegemann Jan 1987 A
4643184 Mobin-Uddin Feb 1987 A
4646736 Auth et al. Mar 1987 A
4650466 Luther Mar 1987 A
4776337 Palmaz Oct 1988 A
4790812 Hawkins, Jr. et al. Dec 1988 A
4863440 Chin et al. Sep 1989 A
4870953 DonMichael et al. Oct 1989 A
4883458 Shiber Nov 1989 A
4886062 Wiktor Dec 1989 A
4890611 Monfort et al. Jan 1990 A
4898575 Fischell et al. Feb 1990 A
4946440 Hall Aug 1990 A
4960259 Sunnanvader et al. Oct 1990 A
4978341 Niederhauser Dec 1990 A
4981478 Evard et al. Jan 1991 A
5030201 Palestrant Jul 1991 A
5059178 Ya Oct 1991 A
5100423 Fearnot Mar 1992 A
5127626 Hilal et al. Jul 1992 A
5129910 Phan et al. Jul 1992 A
5135484 Wright Aug 1992 A
5154724 Andrews Oct 1992 A
5158533 Strauss et al. Oct 1992 A
5158564 Schnepp-Pesch et al. Oct 1992 A
5192274 Bierman Mar 1993 A
5192286 Phan et al. Mar 1993 A
5192290 Hilal Mar 1993 A
5197485 Grooters Mar 1993 A
5234403 Yoda et al. Aug 1993 A
5242461 Kortenbach et al. Sep 1993 A
5244619 Burnham Sep 1993 A
5329923 Lundquist Jul 1994 A
5360417 Gravener et al. Nov 1994 A
5364345 Lowery et al. Nov 1994 A
5376101 Green et al. Dec 1994 A
5383887 Nadal Jan 1995 A
5389100 Bacich et al. Feb 1995 A
5391152 Patterson et al. Feb 1995 A
5419774 Willard et al. May 1995 A
5421824 Clement et al. Jun 1995 A
5443443 Shiber Aug 1995 A
5456667 Ham et al. Oct 1995 A
5476450 Ruggio Dec 1995 A
5484418 Quiachon et al. Jan 1996 A
5490859 Mische et al. Feb 1996 A
5496365 Sgro Mar 1996 A
5527326 Hermann et al. Jun 1996 A
5549626 Miller et al. Aug 1996 A
5591137 Stevens Jan 1997 A
5639276 Weinstock et al. Jun 1997 A
5653684 Laptewicz et al. Aug 1997 A
5662703 Yurek et al. Sep 1997 A
5746758 Nordgren et al. May 1998 A
5749858 Cramer May 1998 A
5769816 Barbut et al. Jun 1998 A
5782817 Franzel et al. Jul 1998 A
5800457 Gelbfish Sep 1998 A
5827229 Auth et al. Oct 1998 A
5846251 Hart Dec 1998 A
5860938 Lafontaine et al. Jan 1999 A
5873866 Kondo et al. Feb 1999 A
5873882 Straub et al. Feb 1999 A
5876414 Straub Mar 1999 A
5895406 Gray et al. Apr 1999 A
5908435 Samuels Jun 1999 A
5911710 Barry et al. Jun 1999 A
5911733 Parodi Jun 1999 A
5911754 Kanesaka et al. Jun 1999 A
5941869 Patterson et al. Aug 1999 A
5947985 Imram Sep 1999 A
5954737 Lee Sep 1999 A
5971938 Hart et al. Oct 1999 A
5971958 Zhang Oct 1999 A
5972019 Engelson et al. Oct 1999 A
5974938 Lloyd Nov 1999 A
5989233 Yoon Nov 1999 A
5993483 Gianotti Nov 1999 A
6017335 Burnham Jan 2000 A
6030397 Moneti et al. Feb 2000 A
6059814 Ladd May 2000 A
6066158 Engelson et al. May 2000 A
6068645 Tu May 2000 A
6126635 Simpson et al. Oct 2000 A
6142987 Tsugita Nov 2000 A
6146396 Konya et al. Nov 2000 A
6146403 St. Germain Nov 2000 A
6152144 Lesh et al. Nov 2000 A
6152946 Broome et al. Nov 2000 A
6156055 Ravenscroft Dec 2000 A
6159230 Samuels Dec 2000 A
6165196 Stack et al. Dec 2000 A
6168579 Tsugita Jan 2001 B1
6179859 Bates et al. Jan 2001 B1
6221006 Dubrul et al. Apr 2001 B1
6228060 Howell May 2001 B1
6238412 Dubrul et al. May 2001 B1
6245078 Ouchi Jun 2001 B1
6245089 Daniel et al. Jun 2001 B1
6254571 Hart Jul 2001 B1
6258115 Dubrul Jul 2001 B1
6264663 Cano Jul 2001 B1
6306163 Fitz Oct 2001 B1
6322572 Lee Nov 2001 B1
6350271 Kurz et al. Feb 2002 B1
6361545 Macoviak et al. Mar 2002 B1
6364895 Greenhalgh Apr 2002 B1
6368339 Amplatz Apr 2002 B1
6383205 Samson et al. May 2002 B1
6402771 Palmer et al. Jun 2002 B1
6413235 Parodi Jul 2002 B1
6423032 Parodi Jul 2002 B2
6432122 Gilson et al. Aug 2002 B1
6451036 Heitzmann et al. Sep 2002 B1
6458103 Albert et al. Oct 2002 B1
6475236 Roubin et al. Nov 2002 B1
6485502 Don Michael Nov 2002 B2
6508782 Evans et al. Jan 2003 B1
6511492 Rosenbluth et al. Jan 2003 B1
6514273 Voss et al. Feb 2003 B1
6530923 Dubrul et al. Mar 2003 B1
6530935 Wensel et al. Mar 2003 B2
6540722 Boyle et al. Apr 2003 B1
6544276 Azizi Apr 2003 B1
6544278 Vrba et al. Apr 2003 B1
6544279 Hopkins et al. Apr 2003 B1
6551342 Shen et al. Apr 2003 B1
6564828 Ishida May 2003 B1
6569181 Burns May 2003 B1
6575995 Huter et al. Jun 2003 B1
6589263 Hopkins et al. Jul 2003 B1
6589264 Barbut et al. Jul 2003 B1
6596011 Johnson et al. Jul 2003 B2
6602271 Adams et al. Aug 2003 B2
6605074 Zadno-azizi et al. Aug 2003 B2
6605102 Mazzocchi et al. Aug 2003 B1
6610077 Hancock et al. Aug 2003 B1
6620148 Tsugita Sep 2003 B1
6620179 Brook et al. Sep 2003 B2
6620182 Khosravi et al. Sep 2003 B1
6623460 Heck Sep 2003 B1
6635068 Dubrul et al. Oct 2003 B1
6645222 Parodi et al. Nov 2003 B1
6660013 Rabiner et al. Dec 2003 B2
6660014 Demarais et al. Dec 2003 B2
6663650 Sepetka et al. Dec 2003 B2
6692504 Kurz et al. Feb 2004 B2
6699260 Dubrul et al. Mar 2004 B2
6702830 Demarais et al. Mar 2004 B1
6719717 Johnson et al. Apr 2004 B1
6755847 Eskuri Jun 2004 B2
6767353 Shiber Jul 2004 B1
6790204 Zadno-azizi et al. Sep 2004 B2
6800080 Bates Oct 2004 B1
6818006 Douk et al. Nov 2004 B2
6824545 Sepetka et al. Nov 2004 B2
6824550 Noriega et al. Nov 2004 B1
6824553 Gene et al. Nov 2004 B1
6830561 Jansen et al. Dec 2004 B2
6846029 Ragner et al. Jan 2005 B1
6902540 Dorros et al. Jun 2005 B2
6939361 Kleshinski Sep 2005 B1
6942682 Vrba et al. Sep 2005 B2
6945977 Demarais et al. Sep 2005 B2
6960189 Bates et al. Nov 2005 B2
6960222 Vo et al. Nov 2005 B2
7004931 Hogendijk Feb 2006 B2
7004954 Voss et al. Feb 2006 B1
7036707 Aota et al. May 2006 B2
7041084 Fotjik May 2006 B2
7052500 Bashiri et al. May 2006 B2
7056328 Arnott Jun 2006 B2
7063707 Bose et al. Jun 2006 B2
7069835 Nishri et al. Jul 2006 B2
7094249 Thomas et al. Aug 2006 B1
7122034 Belhe et al. Oct 2006 B2
7128073 van der Burg et al. Oct 2006 B1
7152605 Khairkhahan et al. Dec 2006 B2
7179273 Palmer et al. Feb 2007 B1
7223253 Hogendijk May 2007 B2
7232432 Fulton, III et al. Jun 2007 B2
7244243 Lary Jul 2007 B2
7285126 Sepetka et al. Oct 2007 B2
7300458 Henkes et al. Nov 2007 B2
7306618 Demond et al. Dec 2007 B2
7320698 Eskuri Jan 2008 B2
7323002 Johnson et al. Jan 2008 B2
7331980 Dubrul et al. Feb 2008 B2
7481805 Magnusson Jan 2009 B2
7534234 Fotjik May 2009 B2
7578830 Kusleika et al. Aug 2009 B2
7621870 Berrada et al. Nov 2009 B2
7674247 Fotjik Mar 2010 B2
7678131 Muller Mar 2010 B2
7691121 Rosenbluth et al. Apr 2010 B2
7695458 Belley et al. Apr 2010 B2
7713282 Frazier et al. May 2010 B2
7722641 van der Burg et al. May 2010 B2
7763010 Evans et al. Jul 2010 B2
7766934 Pal et al. Aug 2010 B2
7775501 Kees Aug 2010 B2
7780696 Daniel et al. Aug 2010 B2
7815608 Schafersman et al. Oct 2010 B2
7905877 Oscar et al. Mar 2011 B1
7905896 Straub Mar 2011 B2
7938809 Lampropoulos et al. May 2011 B2
7938820 Webster et al. May 2011 B2
7967790 Whiting et al. Jun 2011 B2
7976511 Fotjik Jul 2011 B2
7993302 Hebert et al. Aug 2011 B2
7993363 Demond et al. Aug 2011 B2
8021351 Boldenow et al. Sep 2011 B2
8043313 Krolik et al. Oct 2011 B2
8052640 Fiorella et al. Nov 2011 B2
8057496 Fischer, Jr. Nov 2011 B2
8057497 Raju et al. Nov 2011 B1
8066757 Ferrera et al. Nov 2011 B2
8070694 Galdonik et al. Dec 2011 B2
8070769 Broome Dec 2011 B2
8070791 Ferrera et al. Dec 2011 B2
8075510 Aklog et al. Dec 2011 B2
8080032 van der Burg et al. Dec 2011 B2
8088140 Ferrera et al. Jan 2012 B2
8092486 Berrada et al. Jan 2012 B2
8100935 Rosenbluth et al. Jan 2012 B2
8109962 Pal Feb 2012 B2
8118829 Carrison et al. Feb 2012 B2
8197493 Ferrera et al. Jun 2012 B2
8246641 Osborne et al. Aug 2012 B2
8261648 Marchand et al. Sep 2012 B1
8267897 Wells Sep 2012 B2
8298257 Sepetka et al. Oct 2012 B2
8317748 Fiorella et al. Nov 2012 B2
8337450 Fotjik Dec 2012 B2
RE43902 Hopkins et al. Jan 2013 E
8343167 Henson Jan 2013 B2
8357178 Grandfield et al. Jan 2013 B2
8361104 Jones et al. Jan 2013 B2
8409215 Sepetka et al. Apr 2013 B2
8480708 Kassab et al. Jul 2013 B2
8486105 Demond et al. Jul 2013 B2
8491539 Fotjik Jul 2013 B2
8512352 Martin Aug 2013 B2
8523897 van der Burg et al. Sep 2013 B2
8535283 Heaton et al. Sep 2013 B2
8535334 Martin Sep 2013 B2
8535343 van der Burg et al. Sep 2013 B2
8545526 Martin et al. Oct 2013 B2
8568432 Straub Oct 2013 B2
8568465 Freudenthal et al. Oct 2013 B2
8574262 Ferrera et al. Nov 2013 B2
8579915 French et al. Nov 2013 B2
8585713 Ferrera et al. Nov 2013 B2
8608754 Wensel et al. Dec 2013 B2
8647367 Kassab et al. Feb 2014 B2
8657867 Dorn et al. Feb 2014 B2
8696622 Fiorella et al. Apr 2014 B2
8715314 Janardhan et al. May 2014 B1
8721714 Kelley May 2014 B2
8753322 Hu et al. Jun 2014 B2
8771289 Mohiuddin et al. Jul 2014 B2
8777893 Malewicz Jul 2014 B2
8784441 Rosenbluth et al. Jul 2014 B2
8784442 Jones et al. Jul 2014 B2
8784469 Kassab Jul 2014 B2
8795305 Martin et al. Aug 2014 B2
8795345 Grandfield et al. Aug 2014 B2
8801748 Martin Aug 2014 B2
8808259 Walton et al. Aug 2014 B2
8814927 Shin et al. Aug 2014 B2
8820207 Marchand et al. Sep 2014 B2
8826791 Thompson et al. Sep 2014 B2
8828044 Aggerholm et al. Sep 2014 B2
8833224 Thompson et al. Sep 2014 B2
8834519 van der Burg et al. Sep 2014 B2
8845621 Fotjik Sep 2014 B2
8852205 Brady et al. Oct 2014 B2
8852226 Gilson et al. Oct 2014 B2
8939991 Krolik et al. Jan 2015 B2
8945143 Ferrera et al. Feb 2015 B2
8945172 Ferrera et al. Feb 2015 B2
8956384 Berrada et al. Feb 2015 B2
8992504 Castella et al. Mar 2015 B2
9005172 Chung Apr 2015 B2
9011551 Oral et al. Apr 2015 B2
9028401 Bacich et al. May 2015 B1
9078682 Lenker et al. Jul 2015 B2
9101382 Krolik et al. Aug 2015 B2
9125683 Farhangnia et al. Sep 2015 B2
9126016 Fulton Sep 2015 B2
9149609 Ansel et al. Oct 2015 B2
9155552 Ulm, III Oct 2015 B2
9161766 Slee et al. Oct 2015 B2
9168043 van der Burg et al. Oct 2015 B2
9173668 Ulm, III Nov 2015 B2
9186487 Dubrul et al. Nov 2015 B2
9204887 Cully et al. Dec 2015 B2
9216277 Myers Dec 2015 B2
9241669 Pugh et al. Jan 2016 B2
9358037 Farhangnia et al. Jan 2016 B2
9259237 Quick et al. Feb 2016 B2
9265512 Carrison et al. Feb 2016 B2
9283066 Hopkins et al. Mar 2016 B2
9301769 Brady et al. Apr 2016 B2
9351747 Kugler et al. May 2016 B2
9439664 Sos Sep 2016 B2
9439751 White et al. Sep 2016 B2
9456834 Folk Oct 2016 B2
9463035 Greenhalgh et al. Oct 2016 B1
9463036 Brady et al. Oct 2016 B2
9526864 Quick Dec 2016 B2
9526865 Quick Dec 2016 B2
9532792 Galdonik et al. Jan 2017 B2
9566073 Kassab et al. Feb 2017 B2
9566424 Pessin Feb 2017 B2
9579116 Nguyen et al. Feb 2017 B1
9581942 Shippert Feb 2017 B1
9616213 Furnish et al. Apr 2017 B2
9636206 Nguyen et al. May 2017 B2
9643035 Mastenbroek May 2017 B2
9662129 Galdonik et al. May 2017 B2
9700332 Marchand et al. Jul 2017 B2
9717488 Kassab et al. Aug 2017 B2
9717514 Martin et al. Aug 2017 B2
9717519 Rosenbluth et al. Aug 2017 B2
9744024 Nguyen et al. Aug 2017 B2
9757137 Krolik et al. Sep 2017 B2
9827084 Bonnette et al. Nov 2017 B2
9844386 Nguyen et al. Dec 2017 B2
9844387 Marchand et al. Dec 2017 B2
9848975 Hauser Dec 2017 B2
9849014 Kusleika Dec 2017 B2
9884387 Plha Feb 2018 B2
9962178 Greenhalgh et al. May 2018 B2
9980813 Eller May 2018 B2
9999493 Nguyen et al. Jun 2018 B2
10004531 Rosenbluth et al. Jun 2018 B2
10010335 Greenhalgh et al. Jul 2018 B2
10016266 Hauser Jul 2018 B2
10028759 Wallace et al. Jul 2018 B2
10045790 Cox et al. Aug 2018 B2
10058339 Galdonik et al. Aug 2018 B2
10098651 Marchand et al. Oct 2018 B2
10130385 Farhangnia et al. Nov 2018 B2
10183159 Nobles et al. Jan 2019 B2
10226263 Look et al. Mar 2019 B2
10238406 Cox et al. Mar 2019 B2
10271864 Greenhalgh et al. Apr 2019 B2
10327883 Yachia Jun 2019 B2
10335186 Rosenbluth et al. Jul 2019 B2
10342571 Marchand et al. Jul 2019 B2
10349960 Quick Jul 2019 B2
10383644 Molaei et al. Aug 2019 B2
10384034 Carrison et al. Aug 2019 B2
10456555 Carrison et al. Oct 2019 B2
10478535 Ogle Nov 2019 B2
10485952 Carrison et al. Nov 2019 B2
10524811 Marchand et al. Jan 2020 B2
10531883 Deville et al. Jan 2020 B1
10588655 Rosenbluth et al. Mar 2020 B2
10648268 Jaffrey et al. May 2020 B2
10695159 Hauser Jun 2020 B2
10709471 Rosenbluth et al. Jul 2020 B2
10772636 Kassab et al. Sep 2020 B2
10799331 Hauser Oct 2020 B2
10912577 Marchand et al. Feb 2021 B2
10926060 Stern et al. Feb 2021 B2
10953195 Jalgaonkar et al. Mar 2021 B2
10960114 Goisis Mar 2021 B2
11000682 Merritt et al. May 2021 B2
11013523 Arad Hadar May 2021 B2
11058445 Cox et al. Jul 2021 B2
11058451 Marchand et al. Jul 2021 B2
11065019 Chou et al. Jul 2021 B1
11147571 Cox et al. Oct 2021 B2
11154314 Quick Oct 2021 B2
11166703 Kassab et al. Nov 2021 B2
11185664 Carrison et al. Nov 2021 B2
11224450 Chou et al. Jan 2022 B2
11224721 Carrison et al. Jan 2022 B2
11259821 Buck et al. Mar 2022 B2
11305094 Carrison et al. Apr 2022 B2
11383064 Carrison et al. Jul 2022 B2
11395903 Carrison et al. Jul 2022 B2
11406801 Fojtik et al. Aug 2022 B2
11433218 Quick et al. Sep 2022 B2
11439799 Buck et al. Sep 2022 B2
11457936 Buck et al. Oct 2022 B2
11529158 Hauser Dec 2022 B2
11554005 Merritt et al. Jan 2023 B2
11559382 Merritt et al. Jan 2023 B2
11576691 Chou et al. Feb 2023 B2
11596768 Stern et al. Mar 2023 B2
11642209 Merritt et al. May 2023 B2
11648028 Rosenbluth et al. May 2023 B2
11697011 Merritt et al. Jul 2023 B2
11697012 Merritt et al. Jul 2023 B2
11744691 Merritt et al. Sep 2023 B2
11806033 Marchand et al. Nov 2023 B2
11832837 Hauser Dec 2023 B2
11832838 Hauser Dec 2023 B2
11833023 Merritt et al. Dec 2023 B2
11839393 Hauser Dec 2023 B2
20010004699 Gittings et al. Jun 2001 A1
20010031981 Evans et al. Oct 2001 A1
20010041909 Tsugita et al. Nov 2001 A1
20010049486 Evans et al. Dec 2001 A1
20010051810 Dubrul et al. Dec 2001 A1
20020022858 Demond et al. Feb 2002 A1
20020022859 Hogendijk Feb 2002 A1
20020026211 Khosravi et al. Feb 2002 A1
20020032455 Boock et al. Mar 2002 A1
20020049452 Kurz et al. Apr 2002 A1
20020095161 Dhindsa Jul 2002 A1
20020095171 Belef Jul 2002 A1
20020111648 Kusleika et al. Aug 2002 A1
20020120277 Hauschild et al. Aug 2002 A1
20020147458 Hiblar et al. Oct 2002 A1
20020151918 Lafontaine et al. Oct 2002 A1
20020156457 Fisher Oct 2002 A1
20020161392 Dubrul Oct 2002 A1
20020169474 Kusleika Nov 2002 A1
20020173819 Leeflang et al. Nov 2002 A1
20020188276 Evans et al. Dec 2002 A1
20030023263 Krolik et al. Jan 2003 A1
20030083693 Daniel et al. May 2003 A1
20030100919 Hopkins et al. May 2003 A1
20030114875 Sjostrom Jun 2003 A1
20030116731 Hartley Jun 2003 A1
20030125663 Coleman et al. Jul 2003 A1
20030135151 Deng Jul 2003 A1
20030135230 Massey et al. Jul 2003 A1
20030135258 Andreas et al. Jul 2003 A1
20030153873 Luther et al. Aug 2003 A1
20030153973 Soun et al. Aug 2003 A1
20030168068 Poole et al. Sep 2003 A1
20030176884 Berrada et al. Sep 2003 A1
20030191516 Weldon et al. Oct 2003 A1
20030208224 Broome Nov 2003 A1
20030216774 Larson Nov 2003 A1
20040019310 Hogendijk Jan 2004 A1
20040039351 Barrett Feb 2004 A1
20040039412 Isshiki et al. Feb 2004 A1
20040068288 Palmer et al. Apr 2004 A1
20040073243 Sepetka et al. Apr 2004 A1
20040098033 Leeflang et al. May 2004 A1
20040102807 Kusleika et al. May 2004 A1
20040122359 Wenz et al. Jun 2004 A1
20040127936 Salahieh et al. Jul 2004 A1
20040133232 Rosenbluth et al. Jul 2004 A1
20040138525 Saadat et al. Jul 2004 A1
20040138692 Phung et al. Jul 2004 A1
20040167567 Cano et al. Aug 2004 A1
20040199201 Kellett et al. Oct 2004 A1
20040199202 Dubrul et al. Oct 2004 A1
20040260344 Lyons et al. Dec 2004 A1
20040267272 Henniges et al. Dec 2004 A1
20050004534 Lockwood et al. Jan 2005 A1
20050033172 Dubrul et al. Feb 2005 A1
20050038468 Panetta et al. Feb 2005 A1
20050054995 Barzell et al. Mar 2005 A1
20050055047 Greenhalgh Mar 2005 A1
20050085769 MacMahon et al. Apr 2005 A1
20050085826 Nair et al. Apr 2005 A1
20050085846 Carrison et al. Apr 2005 A1
20050085849 Sepetka et al. Apr 2005 A1
20050119668 Teague et al. Jun 2005 A1
20050177132 Lentz et al. Aug 2005 A1
20050187570 Nguyen et al. Aug 2005 A1
20050203605 Dolan Sep 2005 A1
20050283165 Gadberry Dec 2005 A1
20050283166 Greenhalgh et al. Dec 2005 A1
20050283186 Berrada et al. Dec 2005 A1
20060020286 Niermann Jan 2006 A1
20060042786 West Mar 2006 A1
20060047286 West Mar 2006 A1
20060074401 Ross Apr 2006 A1
20060089533 Ziegler et al. Apr 2006 A1
20060100662 Daniel et al. May 2006 A1
20060155305 Freudenthal et al. Jul 2006 A1
20060173525 Behl et al. Aug 2006 A1
20060195137 Sepetka et al. Aug 2006 A1
20060200221 Malewicz Sep 2006 A1
20060217664 Hattler et al. Sep 2006 A1
20060224177 Finitsis Oct 2006 A1
20060229645 Bonnette et al. Oct 2006 A1
20060247500 Voegele et al. Nov 2006 A1
20060253145 Lucas Nov 2006 A1
20060264905 Eskridge et al. Nov 2006 A1
20060276874 Wilson et al. Dec 2006 A1
20060282111 Morsi Dec 2006 A1
20060293696 Fahey et al. Dec 2006 A1
20070010787 Hackett et al. Jan 2007 A1
20070038225 Osborne Feb 2007 A1
20070093744 Elmaleh Apr 2007 A1
20070112374 Paul, Jr. et al. May 2007 A1
20070118165 DeMello et al. May 2007 A1
20070149996 Coughlin Jun 2007 A1
20070161963 Smalling Jul 2007 A1
20070179513 Deutsch Aug 2007 A1
20070191866 Palmer et al. Aug 2007 A1
20070198028 Miloslavski et al. Aug 2007 A1
20070208361 Okushi et al. Sep 2007 A1
20070208367 Fiorella et al. Sep 2007 A1
20070213753 Waller Sep 2007 A1
20070213765 Adams et al. Sep 2007 A1
20070233043 Dayton et al. Oct 2007 A1
20070255252 Mehta Nov 2007 A1
20070288054 Tanaka et al. Dec 2007 A1
20080015541 Rosenbluth et al. Jan 2008 A1
20080087853 Kees Apr 2008 A1
20080088055 Ross Apr 2008 A1
20080157017 Macatangay et al. Jul 2008 A1
20080167678 Morsi Jul 2008 A1
20080183136 Lenker et al. Jul 2008 A1
20080228209 DeMello et al. Sep 2008 A1
20080234715 Pesce et al. Sep 2008 A1
20080234722 Bonnette et al. Sep 2008 A1
20080262528 Martin Oct 2008 A1
20080269798 Ramzipoor et al. Oct 2008 A1
20080294096 Uber, III et al. Nov 2008 A1
20080300466 Gresham Dec 2008 A1
20080312681 Ansel et al. Dec 2008 A1
20090018566 Escudero et al. Jan 2009 A1
20090054918 Henson Feb 2009 A1
20090062841 Amplatz et al. Mar 2009 A1
20090069828 Martin et al. Mar 2009 A1
20090076417 Jones Mar 2009 A1
20090160112 Ostrovsky Jun 2009 A1
20090163846 Aklog et al. Jun 2009 A1
20090182362 Thompson et al. Jul 2009 A1
20090192495 Ostrovsky et al. Jul 2009 A1
20090281525 Harding et al. Nov 2009 A1
20090292307 Razack Nov 2009 A1
20090299393 Martin et al. Dec 2009 A1
20100016837 Howat Jan 2010 A1
20100030256 Dubrul et al. Feb 2010 A1
20100042136 Berrada et al. Feb 2010 A1
20100087844 Fischer, Jr. Apr 2010 A1
20100087850 Razack Apr 2010 A1
20100094201 Mallaby Apr 2010 A1
20100106081 Brandeis Apr 2010 A1
20100114017 Lenker et al. May 2010 A1
20100114113 Dubrul et al. May 2010 A1
20100121312 Gielenz et al. May 2010 A1
20100137846 Desai Jun 2010 A1
20100190156 Van Wordragen et al. Jul 2010 A1
20100204712 Mallaby Aug 2010 A1
20100217276 Garrison et al. Aug 2010 A1
20100249815 Jantzen et al. Sep 2010 A1
20100268264 Bonnette et al. Oct 2010 A1
20100318178 Rapaport et al. Dec 2010 A1
20110034986 Chou et al. Feb 2011 A1
20110034987 Kennedy Feb 2011 A1
20110054405 Whiting et al. Mar 2011 A1
20110060212 Slee et al. Mar 2011 A1
20110071503 Takagi et al. Mar 2011 A1
20110118817 Gunderson et al. May 2011 A1
20110125181 Brady et al. May 2011 A1
20110144592 Wong et al. Jun 2011 A1
20110152823 Mohiuddin et al. Jun 2011 A1
20110152889 Ashland Jun 2011 A1
20110152993 Marchand et al. Jun 2011 A1
20110160742 Ferrera et al. Jun 2011 A1
20110160763 Ferrera et al. Jun 2011 A1
20110190806 Wittens Aug 2011 A1
20110196309 Wells Aug 2011 A1
20110196414 Porter et al. Aug 2011 A1
20110213290 Chin et al. Sep 2011 A1
20110213403 Aboytes Sep 2011 A1
20110224707 Miloslavski et al. Sep 2011 A1
20110245807 Sakata et al. Oct 2011 A1
20110251629 Galdonik et al. Oct 2011 A1
20110264133 Hanlon et al. Oct 2011 A1
20110265681 Allen et al. Nov 2011 A1
20110288529 Fulton Nov 2011 A1
20110288572 Martin Nov 2011 A1
20110309037 Lee Dec 2011 A1
20110319917 Ferrera et al. Dec 2011 A1
20120059309 di Palma et al. Mar 2012 A1
20120059356 di Palma et al. Mar 2012 A1
20120083824 Berrada et al. Apr 2012 A1
20120083868 Shrivastava Apr 2012 A1
20120089216 Rapaport et al. Apr 2012 A1
20120101480 Ingle et al. Apr 2012 A1
20120101510 Lenker et al. Apr 2012 A1
20120109109 Kaji May 2012 A1
20120138832 Townsend Jun 2012 A1
20120143239 Aklog et al. Jun 2012 A1
20120165919 Cox et al. Jun 2012 A1
20120172918 Fifer et al. Jul 2012 A1
20120179181 Straub et al. Jul 2012 A1
20120197277 Stinis Aug 2012 A1
20120232655 Lorrison et al. Sep 2012 A1
20120271105 Nakamura et al. Oct 2012 A1
20120271231 Agrawal Oct 2012 A1
20120277788 Cattaneo Nov 2012 A1
20120310166 Huff Dec 2012 A1
20130030460 Marks et al. Jan 2013 A1
20130035628 Garrison et al. Feb 2013 A1
20130046332 Jones et al. Feb 2013 A1
20130066348 Fiorella et al. Mar 2013 A1
20130092012 Marchand et al. Apr 2013 A1
20130096571 Massicotte et al. Apr 2013 A1
20130102996 Strauss Apr 2013 A1
20130116708 Ziniti et al. May 2013 A1
20130116721 Takagi et al. May 2013 A1
20130126559 Cowan et al. May 2013 A1
20130144326 Brady et al. Jun 2013 A1
20130150793 Beissel et al. Jun 2013 A1
20130165871 Fiorella et al. Jun 2013 A1
20130184703 Shireman et al. Jul 2013 A1
20130197454 Shibata et al. Aug 2013 A1
20130197567 Brady et al. Aug 2013 A1
20130204297 Melsheimer et al. Aug 2013 A1
20130226196 Smith Aug 2013 A1
20130270161 Kumar et al. Oct 2013 A1
20130281788 Garrison Oct 2013 A1
20130289608 Tanaka et al. Oct 2013 A1
20130317589 Martin et al. Nov 2013 A1
20130345739 Brady et al. Dec 2013 A1
20140005712 Martin Jan 2014 A1
20140005713 Bowman Jan 2014 A1
20140005715 Castella et al. Jan 2014 A1
20140005717 Martin et al. Jan 2014 A1
20140025048 Ward Jan 2014 A1
20140031856 Martin Jan 2014 A1
20140046133 Nakamura et al. Feb 2014 A1
20140046243 Ray et al. Feb 2014 A1
20140052161 Cully et al. Feb 2014 A1
20140074144 Shrivastava et al. Mar 2014 A1
20140121672 Folk May 2014 A1
20140155830 Bonnette et al. Jun 2014 A1
20140155980 Turjman Jun 2014 A1
20140180055 Glynn et al. Jun 2014 A1
20140180397 Gerberding et al. Jun 2014 A1
20140155908 Rosenbluth et al. Jul 2014 A1
20140188127 Dubrul et al. Jul 2014 A1
20140188143 Martin et al. Jul 2014 A1
20140222070 Belson et al. Aug 2014 A1
20140236219 Dubrul et al. Aug 2014 A1
20140243882 Ma Aug 2014 A1
20140257253 Jemison Sep 2014 A1
20140257363 Lippert Sep 2014 A1
20140276403 Follmer et al. Sep 2014 A1
20140296868 Garrison et al. Oct 2014 A1
20140303658 Bonnette et al. Oct 2014 A1
20140318354 Thompson et al. Oct 2014 A1
20140324091 Rosenbluth et al. Oct 2014 A1
20140330286 Wallace et al. Nov 2014 A1
20140336691 Jones et al. Nov 2014 A1
20140343593 Chin et al. Nov 2014 A1
20140364896 Consigny Dec 2014 A1
20140371779 Vale et al. Dec 2014 A1
20150005781 Lund-Clausen et al. Jan 2015 A1
20150005792 Ahn Jan 2015 A1
20150018859 Quick et al. Jan 2015 A1
20150018860 Quick Jan 2015 A1
20150018929 Martin et al. Jan 2015 A1
20150025555 Sos Jan 2015 A1
20150032144 Holloway Jan 2015 A1
20150059908 Mollen Mar 2015 A1
20150088190 Jensen Mar 2015 A1
20150127035 Trapp et al. May 2015 A1
20150133990 Davidson May 2015 A1
20150150672 Ma Jun 2015 A1
20150164523 Brady et al. Jun 2015 A1
20150164666 Johnson et al. Jun 2015 A1
20150173782 Garrison et al. Jun 2015 A1
20150190155 Ulm, III Jul 2015 A1
20150190156 Ulm, III Jul 2015 A1
20150196380 Berrada et al. Jul 2015 A1
20150196744 Aboytes Jul 2015 A1
20150209058 Ferrera et al. Jul 2015 A1
20150209165 Grandfield et al. Jul 2015 A1
20150238207 Cox et al. Aug 2015 A1
20150250578 Cook et al. Sep 2015 A1
20150265299 Cooper et al. Sep 2015 A1
20150305756 Rosenbluth Oct 2015 A1
20150305859 Eller Oct 2015 A1
20150352325 Quick Dec 2015 A1
20150360001 Quick Dec 2015 A1
20150374391 Quick Dec 2015 A1
20160022293 Dubrul et al. Jan 2016 A1
20160030708 Casiello et al. Feb 2016 A1
20160038267 Allen et al. Feb 2016 A1
20160058540 Don Michael Mar 2016 A1
20160074627 Cottone Mar 2016 A1
20160106353 Schuetz et al. Apr 2016 A1
20160106448 Brady et al. Apr 2016 A1
20160106449 Brady et al. Apr 2016 A1
20160113663 Brady et al. Apr 2016 A1
20160113664 Brady et al. Apr 2016 A1
20160113665 Brady et al. Apr 2016 A1
20160113666 Quick Apr 2016 A1
20160135829 Holochwost et al. May 2016 A1
20160143721 Rosenbluth May 2016 A1
20160151605 Welch et al. Jun 2016 A1
20160192912 Kassab et al. Jul 2016 A1
20160206344 Bruzzi et al. Jul 2016 A1
20160008014 Rosenbluth Aug 2016 A1
20160220741 Garrison et al. Aug 2016 A1
20160228134 Martin et al. Aug 2016 A1
20160262774 Honda Sep 2016 A1
20160262790 Rosenbluth et al. Sep 2016 A1
20160287276 Cox et al. Oct 2016 A1
20160367285 Sos Dec 2016 A1
20170014560 Minskoff et al. Jan 2017 A1
20170021130 Dye Jan 2017 A1
20170037548 Lee Feb 2017 A1
20170042571 Levi Feb 2017 A1
20170049942 Conlan et al. Feb 2017 A1
20170056032 Look et al. Mar 2017 A1
20170058623 Jaffrey et al. Mar 2017 A1
20170079672 Quick Mar 2017 A1
20170086864 Greenhalgh et al. Mar 2017 A1
20170100142 Look et al. Apr 2017 A1
20170105743 Vale et al. Apr 2017 A1
20170105745 Rosenbluth et al. Apr 2017 A1
20170112514 Marchand et al. Apr 2017 A1
20170113005 Linder et al. Apr 2017 A1
20170143359 Nguyen et al. May 2017 A1
20170143938 Ogle et al. May 2017 A1
20170172591 Ulm, III Jun 2017 A1
20170112513 Marchand et al. Jul 2017 A1
20170189041 Cox et al. Jul 2017 A1
20170196576 Long et al. Jul 2017 A1
20170233908 Kroczynski et al. Aug 2017 A1
20170252057 Bonnette et al. Sep 2017 A1
20170265878 Marchand et al. Sep 2017 A1
20170281204 Garrison et al. Oct 2017 A1
20170303939 Greenhalgh et al. Oct 2017 A1
20170303942 Greenhalgh et al. Oct 2017 A1
20170303947 Greenhalgh et al. Oct 2017 A1
20170303948 Wallace et al. Oct 2017 A1
20170319221 Chu Nov 2017 A1
20170325839 Rosenbluth et al. Nov 2017 A1
20170340867 Accisano, II Nov 2017 A1
20170348014 Wallace et al. Dec 2017 A1
20180042623 Batiste Feb 2018 A1
20180042624 Greenhalgh et al. Feb 2018 A1
20180042626 Greenhalgh et al. Feb 2018 A1
20180055999 Bare et al. Mar 2018 A1
20180064453 Garrison et al. Mar 2018 A1
20180064454 Losordo et al. Mar 2018 A1
20180070968 Wallace et al. Mar 2018 A1
20180092652 Marchand et al. Apr 2018 A1
20180104404 Ngo-Chu Apr 2018 A1
20180105963 Quick Apr 2018 A1
20180125512 Nguyen et al. May 2018 A1
20180184912 Al-Ali Jul 2018 A1
20180193043 Marchand et al. Jul 2018 A1
20180236205 Krautkremer et al. Aug 2018 A1
20180250498 Stern et al. Sep 2018 A1
20180256177 Cooper et al. Sep 2018 A1
20180256178 Cox et al. Sep 2018 A1
20180296240 Rosenbluth et al. Oct 2018 A1
20180344339 Cox et al. Dec 2018 A1
20180361116 Quick et al. Dec 2018 A1
20190000492 Casey et al. Jan 2019 A1
20190015298 Beatty et al. Jan 2019 A1
20190046219 Marchand et al. Feb 2019 A1
20190070401 Merritt et al. Mar 2019 A1
20190117244 Wallace et al. Apr 2019 A1
20190133622 Wallace et al. May 2019 A1
20190133623 Wallace et al. May 2019 A1
20190133624 Wallace et al. May 2019 A1
20190133625 Wallace et al. May 2019 A1
20190133626 Wallace et al. May 2019 A1
20190133627 Wallace et al. May 2019 A1
20190150959 Cox et al. May 2019 A1
20190231373 Quick Aug 2019 A1
20190239910 Brady et al. Aug 2019 A1
20190321071 Marchand et al. Oct 2019 A1
20190336142 Torrie et al. Nov 2019 A1
20190336148 Greenhalgh et al. Nov 2019 A1
20190365395 Tran et al. Dec 2019 A1
20190366036 Jalgaonkar et al. Dec 2019 A1
20200022711 Look et al. Jan 2020 A1
20200046368 Merritt et al. Feb 2020 A1
20200046940 Carrison et al. Feb 2020 A1
20200113412 Jensen Apr 2020 A1
20200121334 Galdonik et al. Apr 2020 A1
20210022843 Hauser Jan 2021 A1
20210038385 Popp et al. Feb 2021 A1
20210113224 Dinh Apr 2021 A1
20210137667 Sonnette et al. May 2021 A1
20210138194 Carrison et al. May 2021 A1
20210186541 Thress Jun 2021 A1
20210205577 Jalgaonkar et al. Jul 2021 A1
20210236148 Marchand et al. Aug 2021 A1
20210290925 Merritt et al. Sep 2021 A1
20210315598 Buck et al. Oct 2021 A1
20210316127 Buck et al. Oct 2021 A1
20210330344 Rosenbluth et al. Oct 2021 A1
20210378694 Thress et al. Dec 2021 A1
20210393278 O'Malley et al. Dec 2021 A1
20210404464 Patoskie Dec 2021 A1
20220000505 Hauser Jan 2022 A1
20220000506 Hauser Jan 2022 A1
20220000507 Hauser Jan 2022 A1
20220015798 Marchand et al. Jan 2022 A1
20220022898 Cox et al. Jan 2022 A1
20220033888 Schnall-Levin et al. Feb 2022 A1
20220039815 Thress et al. Feb 2022 A1
20220125451 Hauser Apr 2022 A1
20220142638 Enright et al. May 2022 A1
20220151647 Dolendo et al. May 2022 A1
20220152355 Dolendo et al. May 2022 A1
20220160381 Hauser May 2022 A1
20220160382 Hauser May 2022 A1
20220160383 Hauser May 2022 A1
20220211400 Cox et al. Jul 2022 A1
20220211992 Merritt et al. Jul 2022 A1
20220240959 Quick Aug 2022 A1
20220346800 Merritt et al. Nov 2022 A1
20220346813 Quick Nov 2022 A1
20220346814 Quick Nov 2022 A1
20220347455 Merritt et al. Nov 2022 A1
20220362512 Quick et al. Nov 2022 A1
20220370761 Chou et al. Nov 2022 A1
20230046775 Quick Feb 2023 A1
20230059721 Chou et al. Feb 2023 A1
20230062809 Merritt et al. Mar 2023 A1
20230070120 Cox et al. Mar 2023 A1
20230122587 Chou et al. Apr 2023 A1
20230200970 Merritt et al. Jun 2023 A1
20230218310 Scheinblum et al. Jul 2023 A1
20230218313 Rosenbluth et al. Jul 2023 A1
20230218383 Merritt et al. Jul 2023 A1
20230233311 Merritt et al. Jul 2023 A1
20230240705 Rosenbluth et al. Aug 2023 A1
20230240706 Rosenbluth et al. Aug 2023 A1
20230241302 Merritt et al. Aug 2023 A1
20230248380 Long et al. Aug 2023 A1
20230270991 Merritt et al. Aug 2023 A1
20230310137 Merritt et al. Oct 2023 A1
20230310138 Merritt et al. Oct 2023 A1
20230310751 Merritt et al. Oct 2023 A1
20230320834 Merritt et al. Oct 2023 A1
20230329734 Marchand et al. Oct 2023 A1
20230338130 Merritt et al. Oct 2023 A1
20230338131 Merritt et al. Oct 2023 A1
20230355259 Marchand et al. Nov 2023 A1
20230355938 Merritt et al. Nov 2023 A1
20230363776 Quick Nov 2023 A1
20230363883 Merritt et al. Nov 2023 A1
20230389932 Ozenne et al. Dec 2023 A1
20230390045 Merritt et al. Dec 2023 A1
Foreign Referenced Citations (106)
Number Date Country
2015210338 Aug 2015 AU
102186427 Sep 2011 CN
103764049 Apr 2014 CN
103932756 Jul 2014 CN
104068910 Oct 2014 CN
106178227 Dec 2016 CN
108348319 Jul 2018 CN
110652645 Jan 2020 CN
111281482 Jun 2020 CN
102017004383 Jul 2018 DE
1254634 Nov 2002 EP
1867290 Feb 2013 EP
2942624 Nov 2015 EP
3583972 Dec 2019 EP
3589348 Jan 2020 EP
3620204 Mar 2020 EP
3013404 Apr 2020 EP
4137070 Feb 2023 EP
1588072 Apr 1981 GB
2498349 Jul 2013 GB
H6190049 Jul 1994 JP
H07323090 Dec 1995 JP
2001522631 May 1999 JP
2004097807 Apr 2004 JP
2005-095242 Jun 2005 JP
2005230132 Sep 2005 JP
2005323702 Nov 2005 JP
2006094876 Apr 2006 JP
2011526820 Jan 2010 JP
WO1997017889 May 1997 WO
WO9833443 Aug 1998 WO
WO9838920 Sep 1998 WO
WO9839053 Sep 1998 WO
WO9851237 Nov 1998 WO
WO1999044542 Sep 1999 WO
WO0032118 Jun 2000 WO
WO2000053120 Sep 2000 WO
WO0202162 Jan 2002 WO
WO03015840 Feb 2003 WO
WO2004018916 Mar 2004 WO
WO2004093696 Nov 2004 WO
WO2005046736 May 2005 WO
WO2006029270 Mar 2006 WO
WO2006110186 Oct 2006 WO
WO2006124307 Nov 2006 WO
WO2007092820 Aug 2007 WO
WO2009082513 Jul 2009 WO
WO2009086482 Jul 2009 WO
WO2009155571 Dec 2009 WO
WO2010002549 Jan 2010 WO
WO2010010545 Jan 2010 WO
WO2010023671 Mar 2010 WO
WO2010049121 May 2010 WO
WO2010102307 Sep 2010 WO
WO2011032712 Mar 2011 WO
WO2011054531 May 2011 WO
WO2011073176 Jun 2011 WO
WO2012009675 Jan 2012 WO
WO2012011097 Jan 2012 WO
WO2012049652 Apr 2012 WO
WO2012065748 May 2012 WO
WO2012120490 Sep 2012 WO
WO2012162437 Nov 2012 WO
WO2014047650 Mar 2014 WO
WO2014081892 May 2014 WO
WO2015006782 Jan 2015 WO
WO2015061365 Apr 2015 WO
WO2015121424 Aug 2015 WO
WO2015179329 Nov 2015 WO
WO2015189354 Dec 2015 WO
WO2015191646 Dec 2015 WO
WO2016014955 Jan 2016 WO
WO2017024258 Feb 2017 WO
WO2017058280 Apr 2017 WO
WO2017070702 Apr 2017 WO
WO2017106877 Jun 2017 WO
WO2017189535 Nov 2017 WO
WO2017189550 Nov 2017 WO
WO2017189591 Nov 2017 WO
WO2017189615 Nov 2017 WO
WO2017210487 Dec 2017 WO
WO2018049317 Mar 2018 WO
WO2018065092 Apr 2018 WO
WO2018080590 May 2018 WO
WO2018148174 Aug 2018 WO
WO2019010318 Jan 2019 WO
WO2019050765 Mar 2019 WO
WO2019075444 Apr 2019 WO
WO2019094456 May 2019 WO
WO2019173475 Sep 2019 WO
WO2019222117 Nov 2019 WO
WO2019246240 Dec 2019 WO
WO2020036809 Feb 2020 WO
WO2021067134 Apr 2021 WO
WO2021076954 Apr 2021 WO
WO2021127202 Jun 2021 WO
WO2021248042 Dec 2021 WO
WO2022032173 Feb 2022 WO
WO2022103848 May 2022 WO
WO2022109021 May 2022 WO
WO2022109034 May 2022 WO
WO2023137341 Jul 2023 WO
WO2023147353 Aug 2023 WO
WO2023154612 Aug 2023 WO
WO2023192925 Oct 2023 WO
WO2023215779 Nov 2023 WO
Non-Patent Literature Citations (61)
Entry
Gibbs, et al., “Temporary Stent as a bail-out device during percutaneous transluminal coronary angioplasty: preliminary clinical experience,” British Heart Journal, 1994, 71:372-377, Oct. 12, 1993, 6 pgs.
Gupta, S. et al., “Acute Pulmonary Embolism Advances in Treatment”, JAPI, Association of Physicians India, Mar. 2008, vol. 56, 185-191.
International Search Report and Written Opinion for International App. No. PCT/US13/61470, dated Jan. 17, 2014, 7 pages.
International Search Report and Written Opinion for International App. No. PCT/US2014/046567, dated Nov. 3, 2014, 13 pages.
International Search Report and Written Opinion for International App. No. PCT/US2014/061645, dated Jan. 23, 2015, 15 pages.
International Search Report for International App. No. PCT/US13/71101, dated Mar. 31, 2014, 4 pages.
Konstantinides, S. et al., “Pulmonary embolism hotline 2012—Recent and expected trials”, Thrombosis and Haemostasis, Jan. 9, 2013:33; 43-50.
Konstantinides, S. et al., “Pulmonary embolism: risk assessment and management”, European Society of Cardiology; European Heart Journal, Sep. 7, 2012:33, 3014-3022.
Kucher, N. et al., “Percutaneous Catheter Thrombectomy Device for Acute Pulmonary Embolism: In Vitro and in Vivo Testing”, Circulation, Sep. 2005:112:e28-e32.
Kucher, N., “Catheter Interventions in Massive Pulmonary Embolism”, Cardiology Rounds, Mar. 2006 vol. 10, Issue 3, 6 pages.
Kucher, N. et al., “Management of Massive Pulmonary Embolism”, Radiology, Sep. 2005:236:3 852-858.
Kucher, N. et al., “Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism.” Circulation, 2014, 129, pp. 9 pages.
Kuo, W. et al., “Catheter-directed Therapy for the Treatment of Massive Pulmonary Embolism: Systematic Review and Meta-analysis of Modern Techniques”, Journal of Vascular and Interventional Radiology, Nov. 2009:20:1431-1440.
Kuo, W. et al., “Catheter-Directed Embolectomy, Fragmentation, and Thrombolysis for the Treatment of Massive Pulmonary Embolism After Failure of Systemic Thrombolysis”, American College of CHEST Physicians 2008: 134:250-254.
Kuo, W. MD, “Endovascular Therapy for Acute Pulmonary Embolism”, Continuing Medical Education Society of Interventional Radiology (“CME”); Journal of Vascular and Interventional Radiology, Feb. 2012: 23:167-179.
Lee, L. et al, “Massive pulmonary embolism: review of management strategies with a focus on catheter-based techniques”, Expert Rev. Cardiovasc. Ther. 8(6), 863-873 (2010).
Liu, S. et al, “Massive Pulmonary Embolism: Treatment with the Rotarex Thrombectomy System”, Cardiovascular Interventional Radiology; 2011: 34:106-113.
Muller-Hulsbeck, S. et al. “Mechanical Thrombectomy of Major and Massive Pulmonary Embolism with Use of the Amplatz Thrombectomy Device”, Investigative Radiology, Jun. 2001:36:6:317-322.
Reekers, J. et al., “Mechanical Thrombectomy for Early Treatment of Massive Pulmonary Embolism”, CardioVascular and Interventional Radiology, 2003: 26:246-250.
Schmitz-Rode et al., “New Mesh Basket for Percutaneous Removal of Wall-Adherent Thrombi in Dialysis Shunts,” Cardiovasc Intervent Radiol 16:7-10 1993 4 pgs.
Schmitz-Rode et al., “Temporary Pulmonary Stent Placement as Emergency Treatment of Pulmonary Embolism,” Journal of the American College of Cardiology, vol. 48, No. 4, 2006 (5 pgs.).
Schmitz-Rode, T. et al., “Massive Pulmonary Embolism: Percutaneous Emergency Treatment by Pigtail Rotation Catheter”, JACC Journal of the American College of Cardiology, Aug. 2000:36:2:375-380.
Spiotta, A et al., “Evolution of thrombectomy approaches and devices for acute stroke: a technical review.” J NeuroIntervent Surg 2015, 7, pp. 7 pages.
Svilaas, T. et al., “Thrombus Aspiration During Primary Percutaneous Coronary Intervention.” The New England Journal of Medicine, 2008, vol. 358, No. 6, 11 pages.
Tapson, V., “Acute Pulmonary Embolism”, The New England Journal of Medicine, Mar. 6, 2008:358:2037-52.
The Penumbra Pivotal Stroke Trial Investigators, “The Penumbra Pivotal Stroke Trial: Safety and Effectiveness of a New Generation of Mechanical Devices for Clot Removal in Intracranial Large Vessel Occlusive Disease.” Stroke, 2009, 40: p. 9 pages.
Truong et al., “Mechanical Thrombectomy of lliocaval Thrombosis Using a Protective Expandable Sheath,” Cardiovasc Intervent Radiol27-254-258, 2004, 5 pgs.
Turk et al., “ADAPT FAST study: a direct aspiration first pass technique for acute stroke thrombectomy.” J NeuroIntervent Surg, vol. 6, 2014, 6 pages.
Uflacker, R., “Interventional Therapy for Pulmonary Embolism”, Journal of Vascular and Interventional Radiology, Feb. 2001: 12:147-164.
Verma, R., MD et al. “Evaluation of a Newly Developed Percutaneous Thrombectomy Basket Device in Sheep With Central Pulmonary Embolisms”, Investigative Radiology, Oct. 2006, 41, 729-734.
International Search Report and Written Opinion for International App. No. PCT/US2015/034987 filed Jun. 9, 2015, Applicant: Inceptus Medical, LLC, dated Sep. 17, 2015, 12 pages.
International Search Report and Written Opinion for International App. No. PCT/US2016/067628 filed Dec. 19, 2016, Applicant: Inari Medical, Inc., dated Apr. 10, 2017, 11 pages.
Goldhaber, S. et al. “Percutaneous Mechanical Thrombectomy for Acute Pulmonary Embolism—A Double-Edged Sword,” American College of CHEST Physicians, Aug. 2007, 132:2, 363-372.
Goldhaber, S., “Advanced treatment strategies for acute pulmonary embolism, including thrombolysis and embolectomy,” Journal of Thrombosis and Haemostasis, 2009: 7 (Suppl. 1): 322-327.
International Search Report and Written Opinion for International App. No. PCT/US2017/029696, Date of Filing: Apr. 26, 2017, Applicant: Inari Medical, Inc., dated Sep. 15, 2017, 19 pages.
International Search Report and Written Opinion for International App. No. PCT/US2016/058536, Date of Filing: Oct. 24, 2016, Applicant: Inari Medical, Inc., dated Mar. 13, 2017, 14 pages.
International Search Report and Written Opinion for International App. No. PCT/US2018/048786, Date of Filing: Aug. 30, 2018, Applicant: Inari Medical, Inc., dated Dec. 13, 2018, 12 pages.
International Search Report and Written Opinion for International App. No. PCT/US2018/055780, Date of Filing: Oct. 13, 2018, Applicant: Inceptus Medical LLC., dated Jan. 22, 2019, 8 pages.
International Search Report and Written Opinion for International App. No. PCT/US2019/045794, Date of Filing: Aug. 8, 2019, Applicant: Inari Medical, Inc., dated Nov. 1, 2019, 17 pages.
International Search Report and Written Opinion for International App. No. PCT/US2020/056067, Date of Filing: Oct. 16, 2020; Applicant: Inari Medical, Inc., dated Jan. 22, 2021, 8 pages.
International Search Report and Written Opinion for International App. No. PCT/US2020/055645, Date of Filing: Dec. 17, 2020; Applicant: Inari Medical, Inc., dated Apr. 14, 2021, 12 pages.
Vorwerk, D. MD, et al., “Use of a Temporary Caval Filter to Assist Percutaneous Iliocaval Thrombectomy: Experimental Results.” SCVIR, 1995, 4 pages.
Wikipedia; Embolectomy; retrieved from the internet: https://en.wikipedia.org/wiki/Embolectomy; 4 pgs.; retrieved/printed: Mar. 24, 2016.
O'Sullivan; Thrombolysis versus thrombectomy in acute deep vein thrombosis; Interventional Cardiology; 3(5); pp. 589-596; Oct. 2011.
Capture Vascular Systems; (company website); retrieved from the internet: http://www.capturevascular.com; 3 pgs.; retrieved/printed: Mar. 24, 2016.
Edwards Lifesciences; Fogarty® Occlusion Catheters (product brochure); retrieved from the internet: http://web.archive.org/web/20150228193218/http://www.edwards.com/products/vascular/atraumaticocclusion/pages/occlusioncatheter.aspx; © 2011; 2 pgs.; retrieved/printed: Mar. 24, 2011.
Boston Scientific; Fetch(TM) 2 Aspiration Catheter (product information);retrieved from the internet: http://www.bostonscientific.com/en-US/products/thrombectomy-systems/fetch2-aspiration-catheter.html; 2 pgs.; retrieved/printed: Mar. 24, 2016.
Penumbra, Inc.; Indigo® System (product information); retrieved from the internet: http://www.penumbrainc.com/peripherallpercutaneous-thromboembolectomy/indigo-system; 7 pgs.; retrieved/printed: Mar. 24, 2016.
Youtube; Merci Retrieval System X Series Animation; uploaded Mar. 16, 2009 (product information); posted on May 7, 2009 by SSMDePaul, time 1:09, retrieved from the internet: https://www.youtube.com/watch?v=MGX7deuFkhc; 3 pgs.; retrieved/printed: Mar. 24, 2016.
Covidien; Solitaire(TM) AS Neurovascular Remodeling Device (product information); retrieved from the internet: http://www.ev3.net/neuro/intl/remodeling-devices/solitaire-ab. htm; © 2015; 2 pgs.; retrieved/printed: Mar. 24, 2016.
International Search Report and Written Opinion for International App. No. PCT/US21/35965, Date of Filing: Jun. 4, 2021, Applicant: Inari Medical, Inc., dated Sep. 28, 2021, 12 pages.
International Search Report and Written Opinion for International App. No. PCT/US21/45072 Date of Filing: Aug. 6, 2021, Applicant: Inari Medical, Inc., dated Jan. 20, 2022, 10 pages.
International Search Report and Written Opinion for International App. No. PCT/US21/58793; Date of Filing: Nov. 10, 2021, Applicant: Inari Medical, Inc., dated Mar. 16, 2022, 13 pages.
International Search Report and Written Opinion for International App. No. PCT/US21/59718; Date of Filing: Nov. 17, 2021, Applicant: Inari Medical, Inc., dated Mar. 22, 2022, 13 pages.
International Search Report and Written Opinion for International App. No. PCT/US21/59735; Date of Filing: Nov. 17, 2021, Applicant: Inari Medical, Inc., dated Mar. 22, 2022, 11 pages.
International Search Report and Written Opinion for International App. No. PCT/US23/60502; Date of Filing: Jan. 11, 2023, Applicant: Inari Medical, Inc., dated May 25, 2023, 9 pages.
International Search Report and Written Opinion for International App. No. PCT/US23/61256; Date of Filing: Jan. 25, 2023, Applicant: Inari Medical, Inc., dated Jun. 7, 2023, 8 pages.
Gross et al., “Dump the pump: manual aspiration thrombectomy (MAT) with a syringe is technically effective, expeditious, and cost-efficient,” J NeuroIntervent Surg, 2018, 4 pages.
International Search Report and Written Opinion for International App. No. PCT/US23/60927; Date of Filing: Jan. 19, 2023, Applicant: Inari Medical, Inc., dated Jul. 20, 2023, 12 pages.
Extended European Search Report issued for EP Application No. 20877370.5, dated Oct. 17, 2023, 11 pages.
International Search Report and Written Opinion for International App. No. PCT/US23/65128; Date of Filing: Mar. 30, 2023, Applicant: Inari Medical, Inc., dated Nov. 14, 2023, 14 pages.
Related Publications (1)
Number Date Country
20230355256 A1 Nov 2023 US
Provisional Applications (1)
Number Date Country
62916044 Oct 2019 US
Continuations (1)
Number Date Country
Parent 17072909 Oct 2020 US
Child 18351326 US